stockpick world macro
continu see stock select key believ macro
drug price elect fear wane offer
upsid innov outperform highlight ow-
rate amgn/vrtx large-cap ow-rat
ions/mgnx/inva smid-cap
call overal macro theme
dramat differ use cash larg cap trend innov
drug price elect risk believ investor becom
comfort potenti polit risk therebi potenti
creat volatil sector diminish larg cap focu growth
valu key call see renew
growth outlook conserv guidanc pipelin option driver
multipl expans posit earn revis expect robust
launch trikafta posit aatd data drive stock higher
smid highlight see phii dementia data key derisk
event key under-valued smid potenti pivot data rare
muscl diseas billion dollar potenti step pivot
dmd genetherapi data derisk bull case expect
return posit mdd phiii data phiii readout
underappreci think continu expans crysvita latin
america potenti approval/launch advanc gene
therapi program drive stock addit
believ sustain tymlo perform increas visibl phiii
studi abaloparatid patch drive stock higher also highlight
uw rate despit drug clinic lack clariti
therapi carri next leg growth compani
despit potenti approv phiii data margetuximab
breast cancer limit market opportun
continu see share shift price pressur hurt royalti incom
could provid meaning updat key investor debat
gilead regeneron far biggest headlin like come
move alzheim program fda review expect
signific reaction potenti accept file like
fda advisori committe hear like late earli potenti
approv like late remain skeptic given view
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
data tail stock remain larg potenti upsid
downsid gilead clariti around use capit strateg
plan manag seek transform busi reinvigor
growth key stock perform continu take wait
see approach believ investor focu remain high final
regeneron major strateg competit updat could drive signific
revers out-performance specif strateg side manag
untangl sanofi jv reform could drive better understand
profit launch novarti beovu remain key competit
industri view
begin foreshadow end head
bruis late investor worri drug price lack
lag perform larg cap biotech end sentiment
improv larg cap discrep perform larg cap
smid narrow major theme like continu
persist drug price sector innov believ key
headwind relat drug price overhang like abat given fluid
polit environ clearer growth trajectori across group said
continu see stock pick key theme expect wholesal re-
rate group
tailwind repres high fda flexibl tailwind signific innov
fda accommod review timelin appear expedit fda
flexibl support new therapi enabl biotech pipelin
advanc faster indic expand rapidli number
approv drug broadli in-line higher
compar year prior exhibit importantli approv
drug receiv approv ahead pdufa date exhibit illustr
highli accommod natur expedit timelin fda review note
number acceler approv in-line number
breakthrough design increas accommod natur fda
also reflect progress increas number activ breakthrough
design program increas
breakthrough design mostli grant oncolog
hematolog antivir indic overal drug
approv receiv breakthrough therapi design indic
willing agenc expedit develop novel therapi
diseas unmet need approv drug receiv breakthrough
design year includ limit trikafta small molecul
cystic fibrosi zolgensma gene therapi spinal muscular atrophi
kymriah car-t therapi cell mediat cancer rituxan antibodi
pemphigu vulgari opdivo antibodi certain cancer look
forward understand strategi fda new commission stephen hahn
recent comment new era scienc move
quickli agenc effici agil
collect believ fda continu review applic
effici accommod especi therapi indic
character high unmet need
exhibit number tradit acceler approv time
exhibit approv occur prior pdufa date
fda compani data
anemia beta-th patient
 key tailwind us larg biopharma signific cash put
work drive growth investor requir exhibit cash led
signific activ biopharma acquisit exhibit total
vs surpass level last year
highlight largest occur bristol acquir celgen
major deal involv phii later stage
product differ deal either late-stag phiii
market product
exhibit total cash posit pharma
innov remain import tailwind sector strong track record
drug innov continu reflect fact
approv therapi orphan drug approv drug first-
in-class approv drug first approv us zolgensma
key innov gene therapi approv treatment sma
turn mani key themat investor focus
deliv first pivot dataset exampl bring addit
gene therapi dataset variou indic exampl major dataset expect
includ gene edit therapi data edita pku data
rubiu red cell therapeut biomarin gene therapi pemphigu vulgari
safeti data cabaletta target car-t therapi major advanc remain
key driver investor interest biotech thu clear dataset highlight
innov potenti sector remain key percept driver
valuat remain attract absolut rel basi
absolut basi top panel exhibit forward price-to-earnings ev/ebitda
multipl lowest rang histor level forward price-to-earnings
current discount market level seen sinc
ev/ebitda sector trade discount broader market thu
compar broader market biotech remain attract valuat basi
rel basi lower panel exhibit biotech forward price-to-earnings discount
pharma healthcar wherea forward ev/ebitda small discount
healthcar in-lin pharma last time recent decad
valuat in-lin healthcar sector around
headwind includ uncertainti elect continu drug price risk
biosimilar launch dynam commerci cycl new drug increas
elect risk coupl potenti greater polici propos drug price
healthcar return past elect year quit volatil among
seven recent elect year three year yield posit return two
experienc limit return two experienc signific pullback reflect
signific polit uncertainti healthcar sector associ elect
particular focus congression action senat prescript
drug price reduct act hous lower drug act
winner democrat presidenti nomin nomine
stanc biotechnology/pharmaceut said believ market
like continu worri drug price headwind believ polit
risk relat elect may actual abat could limit
driver sector market anticip
exhibit healthcar total return elect year
drug price debat continu evolv begin trump
administr push amend medicar pay drug focu
legisl peg medicar drug cost price
payment model design lower out-of-pocket expens review medicar
divid four part part involv hospit coverag includ
inpati visit special nurs facil hospic home health servic
part pertain medic coverag includ doctor clinic lab servic
outpati prevent care servic home healthcar physic
occup therapi surgic fee suppli part also known
medicar advantag combin part part cover prescript
drug coverag part drug deliv physician offic drug pick
pharmaci two medicar part would impact biopharma
execut branch trump administr recent depriorit direct govern
negoti drug price signal support grassley-wyden packag includ
modifi part program simplifi lower spend beneficiari out-of-
pocket cost addit secretari said hh plan cut part price
initi propos follow feedback presid beyond part secretari
emphas need provid transpar rebat fee occur
pbm pharmaci payor remov rebat could dramat chang
way drug price addit hh releas formal propos requir
dtc tv advertis drug paid medicare/medicaid cost
month suppli usual cours therapi includ list price wac tv
congress hous current advanc legisl would requir govern
negoti price brand name drug direct competit
market would includ brand-nam drug maximum price negoti
would cap averag price charg countri hous bill
anticip pass senat part may overlap grassley-
wyden packag move end-of-year bill
view view broad overhaul unlik happen risk like
debat market caus broad pressur biopharma certain compani
reli minim price increas maintain profit growth other driven
mainli price chang
innov challeng commerci cycl new drug pace
innov biopharmaceut industri acceler
biotechnolog revolut well way transform effort medicin
result larg increas type novel modal therapi enter
clinic exampl new scientif develop target cancer cell
differentlyfrom bispecif t-cell engag antibodi construct genet
engin chimer antigen receptor cell antibodi drug conjug
increas product life cycl shorten particularli oncolog
number year competit follow-on launch compress dramat
exampl although herceptin avastin enjoy six seven year
market entri compound similar mode action newer
product like keytruda mekinist lynparza littl year two
without competit life-cycle pressur due competit landscap
faster innov cycl even intens reflect number type
bcma-target agent consid bio current
lead posit tidal wave bcma-target agent clinic
develop car-t bispecif antibody-drug conjug
implic biotech compani bio must develop
agil develop capabl inde environ biotech compani
must remain constant state launch readi develop effici system
stay abreast rapidli evolv landscap quickli develop clinic
commerci strateg plan engag partner alli execut launch
new product launch individu product new indic
biosimilar still repres structur headwind industri novemb
fda approv adalimumab product mark approv
biosimilar biolog price competit innov act although
four biosimilar approv end fda
approv numer biosimilar next three year includ approv
fda approv biosimilar less half launch
 yet soon chang announc launch three
biosimilar rituximab bevacizumab trastuzumab expect two
trastuzumab biosimilar launch settlement genentech addit
headwind industri could occur recent aggress risk launch indic
start trend launch risk launch launch
occur patent litig pend two recent at-risk launch
launch mvasi referenc avastin kanjinti referenc
herceptin although defeat preliminari injunct motion file
genentech launch still risk preliminari injunct
decis appeal juri yet determin whether amgen
infring valid claim genentech patent preliminari injunct decis
preliminari decis made court juri make decis addit
sale refer product neulasta heavili impact
entri competit biosimilar market biosimilar compani continu
take aggress posit at-risk launch industri could face strong
headwind beyond
exhibit biosimilar approv fda ema
epogen procrit
epogen procrit
idacio kromeya
exhibit biosimilar file fda ema
exhibit biosimilar late stage develop
exhibit neupogen epogen price decay forecast mse
exhibit neupogen epogen volum decay forecast mse
still rate sensit sector biotech valuat highli
depend larg termin valu driver result biotech valuat
highli sensit chang discount rate us equiti market whole
neg exposur steepen yield curv accord global
equiti strategi team increas yield curv slope associ
decreas expect return biotech continu expect rate
increas see detail highlight known clear
exhibit pharma yield curv level sensit
inflect point ipo cycl
biggest year biotech ipo secondari activ histori involv
deal ipo fo follow-on activ slow deal
although still larg number close level previou ipo/fo
spike importantli despit step-up last privat round
ipo experienc two minor peak valu drop
nadir fourth quarter investor worri earli stage
ipo recent experienc improv sentiment
pivot year term test investor attitud toward new ipo
impact biotech invest gener
exhibit histor number biotech ipo follow-on
exhibit return biotech ipo
thomson reuter morgan stanley research note chart trail day averag delist compani exclud
earli spike return ipo relat stock price perform
expect fund requir rise
recent ipo expect need return market near-term
signifi potenti uptick number follow-on offer sector base
analysi biotech ipo estim larg number
compani requir addit fund expect rise fund
requir signific headwind go year especi amid depress
biotech valuat support claim sum total liquid asset ce
short term invest discret biotech ipo
divid amount oper neg proxi cash
burn determin number quarter compani could sustain
current rate assum compani would need rais enough money secondari
offer support two year continu oper estim aggreg
fund requir amount across compani
exhibit percent biotech compani positive/neg cfo
exhibit count biotech ipo requir
exhibit total follow-on fund requir yr bn mse
anticip patent litig inter part review decis
number signific patent litig decis final written decis inter
part review ipr expect
tecfidera face legal challeng side tecfidera largest product
repres total product revenu estim peak sale
tecfidera protect patent latest patent expir
gener break patent could launch regulatori
exclus end repres potenti major near-term risk
revenu three legal challeng threaten patent first
patent trial appeal board ptab heard oral argument inter part
review ipr brought rule expect second
also challeng patent valid northern district west virginia
expect judg could like rule third six remain gener
drug compani activ challeng patent valid district
delawar also expect judg could like rule
must win settl three disput sustain patent final banner life
scienc sidestep patent seek approv product
fall outsid scope patent claim fact patent
sit final fda approv patent expir
thu assum get final fda approv soon patent expir
tecfidera face competit earli
step elimin soliris-protect patent part effort market
biosimilar alexion soliri file petit inter part review
alexion three key patent protect soliri patent trial
appeal board institut review ptab schedul hear oral argument
issu final written decis patent
found unpatent remain patent protect soliri would
alexion patent set expir march
viiv shionogi patent infring suit gilead biktarvi viiv
healthcar part gsk cover mark purcel shionogi cover
shinichiro muraoka su gilead alleg gilead biktarvi
infring patent expir shionogi alleg patent
origin work gsk novel structur scaffold develop
new gener hiv integras strand transfer inhibitor includ dolutegravir
although shionogi conced patent liter cover biktarvi
shionogi ask court constru patent expans cover
biktarvi gilead file motion judgment plead contend
shionogi preclud matter law patent constru
expans doctrin equival thu biktarvi infring
patent oral argument motion heard trial
schedul note shionogi seek money damag
gilead injunct stop gilead sell biktarvi
author materi act capac attorney hold
materi intend either legal opinion legal
advic inform provid herein provid possibl outcom
probabl outcom result legal disput controversi depend
varieti factor includ limit parti histor relationship law
pertain case rel litig talent trial locat juri composit judg
composit investor contact legal advisor issu law relat
subject matter materi
unit state america
repres depart
human servic
unit state america
repres depart
human servic
unit state america
repres depart
human servic
unit state america
repres depart
human servic
univers
univers
univers
univers minnesotagilead
deadlin patent
owner file preliminari
respons two month
later deadlin
file final disposit
petit certiorari
regent univ minn
deadlin patent
owner file preliminari
respons two month
later deadlin
file final disposit
petit certiorari
regent univ minn
deadlin patent
owner file preliminari
respons two month
later deadlin
file final disposit
petit certiorari
regent univ minn
deadlin patent
owner file preliminari
respons two month
later deadlin
file final disposit
petit certiorari
regent univ minn
respons minn
univers minnesota
respons minn
univers minnesota
respons minn
univers minnesota
respons minn
option respons
concert motion
remand unit
state request
appeal decis
concert motion
remand case back
morgan stanley research public access electron record
univers minnesota
oral hear gilead
motion judgment
plead
decis gilead
motion judgment
plead
gilead respons hh
unit state america gilead
disclosur propos
epclusa
univers
case stay
pend disposit
ipr file
court deni juno
kite motion
reconsider
option petit panel
rehear rehear en
banc merck
regent univers
motion
deni moot
stay
motion
judgment
plead
court
court decid
motion judgment
plead
alexion answer
propos order
morgan stanley research unit state patent trademark offic
answser
sorafenib
industri debat view
drug price elect risk alreadi price
debat elect move view investor increasingli focus
potenti risk industri domin headlin variou drug
price propos presid trump democrat presidenti candid
propos evolv elect enter final year impact
view debat evolv legisl move senat becom
clear probabl pass price bill elect lower
previous expect side push differ outcom differ
approach doesnt look like either side polit capit enact
signific chang given develop believ price pressur price
market lead inflect point begin
begin see valuat turn around debat remain regard elect risk
overhang believ parti run messag drug price reform
uncertainti around action legisl fall remain taken
lead role adjust new price environ gilead
lower list price key drug limit brand price increas
said still expect price inflat compani though
would expect moder increas rang overal believ biotech biggest
risk chang medicar part given sector high exposur large-molecul
happen downsid price
debat trump administr attempt amend medicar pay
drug review medicar divid four part part involv
hospit coverag includ inpati visit special nurs facil hospic
home health servic part pertain medic coverag includ doctor
clinic lab servic outpati prevent care servic home healthcar
physic occup therapi surgic fee suppli part also known
medicar advantag combin part part cover prescript drug
coverag part drug deliv physician offic part drug pick
pharmaci two medicar part would impact biopharma
part b-target intern price index demo project trump
administr propos demo project would cover approxim half
us set medicar payment amount select part drug
phase close align intern price via intern
price payment model pleas see previou note
part d-target potenti chang protect class medicar
advantag demo protect class group drug part plan must
antipsychot antiretrovir immunosuppress result
protect drug typic insul price pressur
propos rule allow plan exclud formulari drug class
price increas greater inflat well new drug formul
signific innov origin product addit
propos use prior author step therapi protect class drug
medicar advantag also propos allow greater formulari control
includ broad exclus certain drug commerci plan tactic
use drive lower price manufactur
rebat transpar secretari emphas need provid transpar
rebat fee occur pbm pharmaci payor remov
rebat could dramat chang way drug price
drug price transpar hh releas formal propos requir dtc tv
advertis drug paid medicare/medicaid cost
month suppli usual cours therapi includ list price wac tv
view view broad overhaul unlik happen risk like
debat market caus pressur biopharma certain compani reli
minim price increas maintain profit growth other driven
mainli price chang
exhibit price volum summari
specif expect challeng hh part intern refer price
propos predict whether hh would follow plan hh
plan introduc plan would expect happen earli biotech
taken lead role adjust new price environ gilead
lower list price key drug limit brand price increas
said still expect price inflat compani though
would expect moder increas rang overal believ biotech biggest
risk chang medicar part given sector high exposur large-molecul
larg cap biotech re-rat smid continu
debat smid outperform larg cap biotech late
trend revers investor sought defens natur larg cap
wane howev investor debat tailwind innov need larg cap
polit risk sustain larg cap ralli remain open question
view continu expect tug war larg cap amgen
vertex reposit other continu larg tail risk thu
expect investor look favor larg cap
expect wholesal re-rat group
key technolog therapeut area see signific
invest
debat highlight key new technolog alway lead key smid-cap
name could see out-performance genetherapi novel cell edit
technolog main focu ask els could key
emerg technolog focu
view ophthalmolog remain key therapeut area test avv deliveri
gene therapi gene edit approach eye logic approach derisk
potenti safeti issu associ aav given limit immun system exposur
focus clinic updat wamd next year
believ learn advanc technolog system indic
potenti system data could take center stage next year includ dmd
hemoglobinopathi rare diseas pku neurolog remain earli field
signific advanc report almost weekli alzheim diseas major unmet
need return aducanumab potenti compani take second look
therapi target amyloid product overal see field advanc
beyond plaqu clearanc monoclon antibodi includ neuro-immunolog
modulatori approach novel mab gene therapi specif focus
updat ftd/alzheim trial denali program parkinson
key area focu pipelin success
event alway remain mani key event smid large-cap
view number event gener in-lin see mani move
exhibit trial readout time potenti stock movement
present top line data phiii
present top line data phiii
initi infront phii poc data ftd-pgrn patient
phii readout nsclc
top-line readout phiii studi azacitidin md
top-line phiii adapt data includ open-label extens cohort gmg
transcon pth phii studi hypoparathyroid
updat world symposium
top-line phiii result prevent treatment migrain
acut safeti data phi trial mucos pv
interim efficaci readout phiii galactic-hf studi omecamtiv mecarbil hf
potenti readout phi/ii studi
phiia data psoriasi
initi data phiii studi rcc
interim efficaci data pivot phii magrolimab rituximab dlbcl
readout proof concept phiib studi fshd
top-line phiib data osteoarthr roccella
phii readout glpg toledo disclosur moa
phiii confirmatori studi ascent top-lin data mtnbc
phiii data ruxolitinib cream atop dermat
readout non-cyst fibrosi bronchiectasi
phii ole data huntington
phii patient subtyp ib abdomin pain
phiii data persist gerd
phii data ucd
final os analysi phiii sophia analysi
readout phiii explorer-hcm ohcm
proof-of-concept data phii studi solid tumor
month biomark data phi/ii parkinson
initi ph i/ii data type gaucher diseas
interim phiii data nsclc
top-line data pivot bbs/alstrm syndrom trial
initi data pku
final overal surviv analysi pivot hr breast cancer
data phii/phib trial oa knee
initi efficaci data solid tumor studi
data phii studi aatd patient zz mutat
trial stop earli
view major pipelin event across space see data
fulcrum vertex argenx sarepta biggest impact
also highlight key regulatori event expect
exhibit regulatori event expect
type-c meet discuss whether phiib biomark could use surrog endpoint
fda decis acut treatment migrain
potenti fda/ema approv
potenti fda approv non genotyp
potenti fda approv late line therapi
fda decis subq may estimate
potenti fda approv
potenti fda approv
potenti fda approv
fda decis pediatr patient atop dermat
phiii readout launch
debat launch remain key point interest investor expect tend
get ahead perform mani instanc said mani specialti
launch investor focu high stock opportun
phiii data studi genotyp
phiii data studi genotyp
phiii data studi
phiii trial test choroideremia
phii/iii trial test nsr-rpgr x-link retin pigmentosa
phiii interim readout efficaci galactic-hf
interim data phiii trial nsclc
view see potenti regulatori approv catalyst
major focu investor howev launch biomarin genetherapi hemophilia
seattl genet enfortumab vedotin sacituzumab govitecan
remain key focu investor would also note global blood
oxbryta approv late key focu investor well
exhibit weekli trx aimovig vs cgrp sinc launch
exhibit monthli trx prauluent repatha sinc launch
key biosimilar launch
debat number biosimilar approv grown
impact market remain modest investor continu wonder
matter
exhibit approv file biosimilar
exhibit biosimilar late stage develop
view histor biosimilar face legal market impedi
launch howev key drug experienc rapid uptak made
meaning contribut revenu would expect
trend continu look competit base busi
rituxan biosimilar impact potenti develop relat biosimilar
alexion soliri regeneron eylea key factor watch
call
larg cap overweight amgen vertex theme larg cap year
growth valu see name clear potenti outperform driven
improv pipelin upsid launch return growth
ow pt remain one top pick larg cap biotech
acquisit otezla manag transform compani
valu stori growth stori conserv guidanc pipelin
tezepelumab provid signific option driver
vertex ow pt focus strong launch cf tripl trikafta
coupl success initi data manag aatd program drive
exhibit impli upsid larg cap coverag univers base current price
valuat methodolog risk associ price target referenc research report pleas contact client support
sydney tokyo altern may contact invest repres
research broadway attent research manag new york ny usa
would expect smid fertil ground idea
remain mani binari event could drive stock coupl
potenti broad smid-cap ralli begin focu convict
name see signific upsid downsid
sarepta ow pt focus three key driver
first investor concern potenti safeti issu face
dmd program manag finish dose lgmd patient
believ risk major safeti event significantli lower expect
posit impact stock second believ manag
move dose dmd genetherapi patient commerci materi mid-
also posit driver final potenti phiii data expect
genetherapi demonstr benefit could avail importantli
also expect updat manag ppmo technolog could
provid downsid support dmd genetherapi unexpectedli fail
therapeut ow pt failur phiii mountain studi
mani concern believ manag revers
concern posit data redwood shorelin
ow believ initi phii poc data ftd provid
meaning upsid driver believ drug slow ftd relat declin
result lower brain volum loss mri chang nfl key
fulcrum ow see fulcrum one under-valued biotech
cover believ losmapimod success treatment fshd
pivot phii result support acceler file fda
ultragenyx ow pt continu believ share under-valued
current share price support crysvita alon although full
reimburs crysvita latin america take time continu advanc
countri countri basi could ultim prove signific
ultragenyx greater econom geographi also continu think
street ascrib valu gene therapi program remain
construct lastli compani could third approv drug
end juli long-chain fatti acid oxid disord lc-faod
think worth ultragenyx also plan begin studi
angelman syndrom wilson diseas glycogen
storag diseas creatin transport defici
uw pt remain underweight concern share shift
breo/anoro tripl coupl price pressur breo continu
erod royalti base underli valuat
radiu ow pt remain ow continu believ
potenti forteo gener pose little-to-no threat tymlo sale
addit believ current valuat attribut limit credit
abalo-patch elacestr believ greater visibl phiii
wearabl studi abalo-patch throughout could drive signific
investor interest potenti patch result would expect
continu tymlo quarterli perform coupl greater appreci
pipelin option drive higher
uw pt underweight ioni although ioni industri leader
develop drug target rna specif proprietari antisens
technolog compani next stage growth appear uncertain spinraza
blockbust competit dynam market shift
emerg gene therapi progress oral therapi recent approv
tegsedi waylivra approv ex-u late stage drug candid
appear readi provid anoth materi growth driver see
macrogen uw pt underweight macrogen though
margetuximab could approv base inabl differenti os
give us low expect potenti final os data expect
announc respect pipelin drug includ dart bispecif
target enoblituzumab need see
data demonstr suffici efficaci clean profil warm
exhibit impli upsid smid-cap coverag univers base current price
compani data thomson reuter morgan stanley research estim valuat methodolog risk associ price target
referenc research report pleas contact client support follow us/canada hong kong latin
altern may contact invest repres morgan stanley research broadway attent research manag new
ew pt lower pt iqvia script
data trend suggest cabometyx sale
consensu remain equal-weight believ expect
rcc larg price share
ow pt rais pt viela
initi pivot studi inebilizumab myasthenia gravi mg
although reason believ inebilizumab averag chanc
work mg alexion soliri approv nmosd mg
maintain conserv probabl success given inebilizumab
enter clinic mg remain overweight believ inebilizumab
like approv nmosd
voyag ew pt lower pt
street attribut less premium gene therapi compani
earlier year specif ascrib less valu pipelin
lower probabl success huntington program
believ still reason given typic ascrib
probabl success phase asset program yet clinic
believ street ascrib much valu program sinc
still earli remain equal-weight base limit clinic catalyst
edita ew pt increas pt chang
result time revenu model updat assumpt
manag move pipelin forward
global blood ew pt increas pt account
approv oxbryta upsid price long-term peak sale
larg cap debat
ultomiri switch go switch ultomiri continu track
reach convers us management achiev follow
pnh convers figur key geographi us
germani japan strong figur main risk achiev
convers transit high lower volum prescrib
focus earn management highlight switch dynam ahu
differ pnh mani initi patient dose in-pati set
management expect switch ultomiri occur patient leav hospit management
also note patient requir shorter durat treatment
pregnant women may decid stay soliri potenti limit upsid
potenti ahu convers overal believ management exceed target
implic soliri ipr file petit inter part review
alexion three key patent protect soliri patent trial
appeal board institut review ptab hear oral argument
issu final written decis patent found
unpatent remain patent protect soliri would alexion
patent set expir march given ptab lower bar
district court expect ipr remain key overhang head
summer
pipelin option achillion stealth deal continu see long-term
valu investor focus pipelin success help counter
soliri tail concern view achillion acquisit increment pnh
franchis upsid potenti monotherapi danicopan
advanc program could use combin soliris/ultomiri
treat pnh patient experi extravascular hemolysi
remain transfusion-depend danicopan also test patient
estim affect us japan investor focus
monotherapi given nearli complet inhibit ap
danicopan longer test monotherapi catalyst danicopan
includ top-lin phii pnh result combin soliri global regulatori
discuss initi phiii studi pnh management also plan
initi phii poc trial test monotherapi
treatment pnh stealth deal co-develop commerci elamipretid
conting phiii data mitochondri myopathi pmm
expect report top-lin data management decid whether
exercis option phiii studi unblind view deal
low risk invest late stage asset allow alexion leverag
neurolog experi gmg
new revenue/ep compound-annual-growth-rate support multipl pharma peer
novemb management announc complet acquisit otezla
small molecul anti-inflammatori drug indic treatment psoriasi
psoriat arthriti acquir world-wide right celgen later bristol-
myer squibb cash net anticip futur tax benefit
believ transact given estim peak world-wide sale
justifi multipl pharma peer group context
peer group forward price-to-earnings con present
trade forward price-to-earnings multipl base busi prior
acquisit otezla revenu compound-annual-growth-rate ep compound-annual-growth-rate
compar unfavor peer group averag top line compound-annual-growth-rate
bottom line compound-annual-growth-rate follow otezla acquisit howev estim
expans top bottom line compound-annual-growth-rate figur eventu exceed
peer group averag incorpor revenu otezla model
project amgen revenu compound-annual-growth-rate ep compound-annual-growth-rate
win kra race small molecul kra inhibitor
current develop kra part famili ra gene
known commonli mutat oncogen across human cancer
drug target mutat yet commerci leav larg market
opportun asset approv cover also
develop mechanist similar target
kra mutat compani evalu drug nsclc
report phi data achiev orr nsclc
patient pr orr patient pr achiev
orr nsclc patient pr orr patient
pr given small patient pool see data compar howev
investor remain focus compound
demonstr superior increment dataset next clinic updat
expect expect aacr/asco data like
includ phii monotherapi data nsclc along updat cohort
inform combin trial mirati also announc intent
present phii data believ two avenu
success abl commerci drug mirati
manag achiev durabl superior singl indic versu mirati
compound overal believ drive faster path market take
growth legaci vs new product one win competit
biopharmaceut industri intensifi investor becom increasingli focus
legaci portfolio fare versu compani newer product
legaci product epogen neulasta
seen price volum pressur result competitively-pr biosimilar
agent enter market separ legaci product
hyperlipidemia kyproli proteasom inhibitor seen signific organ
growth sinc approv drug patent expiri
respect protect drug exclus
near futur notabl management announc intent make repatha
commerci avail lower list price level believ
potenti boost sale growth futur price reduct like
off-set unit growth newer product howev seen less-than-
impress growth aimovig particular interest seen larg
fluctuat price unit volum sinc approv despit
migrain market remain attract opportun contribut
bullish stanc aimovig futur also part new product
portfolio compani biosimilar remain focus
perform two group drug dynam signific
contributor valuat overal investor sentiment year progress
alzheim alzheim alzheim come increment updat
ctad investor left accept bla earli
inevit fda advisori committe hear expect next key
catalyst aducanumab overal view effect size emerg trial
minim question impact deterior placebo respons
subset analysi becom clear management plan present post hoc
subpopul analysi fda support file investor forc
debat whether potenti signal one phiii trial secur approv
appreci impact enrol time ultim believ data
support investig aducanumab like one biggest
catalyst sector
potenti impact tecfidera patent litig tecfidera face multipl patent
challeng form gener form ipr district court litig
tecfidera largest product repres total product
revenu estim peak sale patent trial appeal
patient expect rule clear bellweth
investor also challeng patient valid northern district
west virginia expect rule final gener
compani challeng patent district delawar also
expect judg could rule management recent settl sever
challeng district court main overhang remain ptab decis
tecfidera repres oper profit win
litig great import
signific current threat spinraza investor focus
defin threat zolgensma discount potenti launch
risdaplam follow posit pivot data zolgensma expect captur
major new incid patient age note spinraza
continu gener growth adult patient higher compar
durabl zolgensma remain key overhang question whether
sprinraza could use combin patient age addit major
spinraza revenu growth came outsid us earn
sequenti fda expect make decis risdiplam base
firefish infant type sma sunfish yoa type
sma trial overal view risdiplam key potenti competitor older
type ii/iii patient could activ switch spinraza risdiplam would
dramat cut key area spinraza growth
gilead buy investor focu remain gilead reinvigor
growth cure investor expect larg acquisit drive transform
chang gilead believ management focu mid-siz deal partnership
biotech see bar transform acquisit high
believ oncolog virolog repres key area focu management see
potenti management expand area therapeut focu
car-t grow time billion acquisit gilead frame kite
take-over part long-term strategi becom leader cell therapi
payoff deal yet materi inde sale yescarta
grow third quarter sale total sequenti
quarterli sale variat partli explain one three headwind
yescarta growth gilead fight clinic trial patient management state
observ car-t elig patient enrol clinic trial much higher
rate rel commerci patient see two headwind yescarta
growth first roch antibody-drug conjug polivi polatuzumab vedotin
compet yescarta b-cell lymphoma market management hasnt given
detail polivi potenti impact yescarta beyond note remain earli
day roch drug launch second car-t field becom crowd
technolog young fluid enough start-up come
nowher technolog chang everyth despit headwind
sever develop fuel yescarta sale increas
reimburs medicar patient improv long-term outcom data
increas center initi use europ gilead continu invest
cell therapi manufactur capabl gener real competit
advantag compet car-t therapiesand signal gilead long-term
commit cell therapi overal car-t market expect see
signific growth due fewer reimburs concern increas physician
educ experi car-t therapi new product launch car-t
cell therapi target cancer type think gilead well posit
enjoy growth note bi-specif antibodi off-the-
shelf technolog continu view key headwind space
sustain hiv franchis sale hiv product billion
account gilead revenu third quarter whether hiv
franchis sustain depend larg part two product big part
sale biktarvi drug hit billion global sale increas
quarter last year third quarter
number one prescrib regimen hiv regimen europ time
number one prescrib regimen treatment-nav switch patent
germani franc spain juli version guidelin use
antiretrovir agent adult adolesc hiv biktarvi
recommend initi use peopl hiv support
continu sale although biktarvi surg newli diagnos patient also
draw gilead drug move descovy-
base regimen one-third truvada anoth third genvoya
switch import truvada genvoya near
patent cliff support biktarvi key posit market continu
strong sale long-term durabl data show biktarvi well-toler
demonstr high rate suppress symptom hiv week
anoth key sustain gilead hiv busi truvada follow-up
descovi big task save billion annual sale switch
mani prep patient possibl truvada descovi gener hit
make happen gilead count increment improv bone
kidney safeti help make case also bulk descovi rep rank
move mani sale rep cardiopulmonari portfolio that hit gener
retrain detail descovi although management yet share
percentag patient switch management mention sever reason
optimist indic earli anecdot evid reflect strong start
overal believ gilead hiv franchis sustain due biktarvi
assumpt management execut switch larg percentag patient
truvada time teva launch gener product septemb
drive multipl potenti catalyst across
pipelin expect howev expect primari area
investor focu phiii data itacitinib first-lin gvhd phiii data
ruxolitinib cream atop dermat quarterli jakafi perform initi
bladder cancer data fgfr inhibitor pemigatinib current valuat level
believ price jakafi long-term sale within management guidanc
also impli signific valu late-stag pipelin asset itacitinib
ruxolitinib cream result believ risk/reward current skew
neg head phiii data itacitinib ruxolitinib cream expect
investor continu focu quarterli jakafi sale particularli outsiz
beat indic jakafi sale could extend meaning beyond
compani long-term sale guidanc prior jakafi patent expir
pemigatinib expect investor compar molecul profil johnson
 johnson balversa erdafitinib fgfr inhibitor current approv treat
bladder cancer particularli safeti lastli note one area could
present potenti upsid driver jakafi life cycl manag management note
ruxolitinib combin data set well updat extended-releas
ruxolitinib could avail meaning posit updat
demonstr potenti extend jakafi franchis beyond would like
gener signific investor enthusiasm estim everi peak
jakafi sale maintain worth valu
itacitinib succeed first-lin gvhd valuabl could
top line data phiii studi evalu oral
inhibitor itacitinib steroid-na acut graft-versus-host diseas agvhd
expect full data studi evalu itacitinib
corticosteroid vs placebo corticosteroid management aim demonstr
improv day orr primari endpoint rel
improv non-relaps mortal nrm key secondari endpoint
itacitinib corticosteroid corticosteroid monotherapi base recent
publish statist analysi see estim
numer separ orr would suffici achiev stat sig
believ probabl success po achiev stat sig
orr estim bayesian po
demonstr desir separ orr nrm hurdl
itacitinib aim demonstr rel risk reduct
estim corticosteroid monotherapi establish nrm six
month base review relev literatur current assign itacitinib
po project launch eu launch
risk-adjust basi believ itacitinib could gener peak global
sale gvhd includ acut chronic gvhd prior patent
expir sum-of-the-part basi itacitinib repres
model base case valuat peak sale estim
attribut itacitinib agvhd attribut chronic gvhd
separ phiii program underway data expect
current itacitinib sale estim predic stat sig
separ orr day meaning separ nrm vs
corticosteroid monotherapi expect top line readout
well full data drive investor percept commerci
viabil itacitinib
ruxolitinib cream succeed atop dermat ruxolitinib cream current
evalu phiii program atop dermat ad vitiligo phiii data
ad expect expect signific investor focu data set
given sizabl unmet need post mild-to-moder ad global
ownership rux cream vs oral ruxolitinib jakafi partner
novarti potenti readout hold establish
dermatolog franchis base phii data present date assign rux
cream po believ phii studi enrol similar patient popul
phiii studi underway gener encourag result regard
easi score iga respons itch score cream also appear safe
phii studi establish view rux cream price uptak potenti assum
phiii readout posit expect investor focu cream daili
usabl profil numer separ efficaci versu topic steroid cream
impact beovu launch eylea revenu eylea main revenu
earn driver regeneron eylea current hold brand market
patient volum wamd repres share investor
focus launch beovu potenti share shift base
week dose regimen survey retina specialist expect beovu
captur signific share wamd market impli drop eylea
market share wamd current eylea consensu estim specialist
expect plan survey group enough
physician dose hand initi patient focus rate
inflamm greatest risk beovu uptak regeneron also initi
phii studi test higher dose eylea wamd expect continu
growth prolif sever non-prolif dr support current
revenu project believ consensu expect inflamm inhibit
beovu uptak thu inflamm significantli hinder uptak see
potenti risk
implic restructur sanofi jv sanoif jv agreement recent
restructur follow cost control drove profit good
leverag us restructur agreement includ regeneron take us
right praluent sanofi take ex-u sanofi retain global right kevzara
parti respons commerci expens
respect territori pay parti royalti base current jv
model project kevzara gener total ep after-tax
profit regeneron praluent expect neg impact
total ep assum regeneron management move praluent break-even
us resourc appropri believ ultim could drive
ep accret await final detail management expect
final transact also await inform management
agreement could streamlin overal report regeneron
manag viabl i/o strategi bispecif investor
continu debat near-term valu libtayo competit
management bispecif pipelin management pursu broad develop approach
lybtayo nsclc expect interim data phiii trial initi
nsclc result encourag believ repres upsid potenti
strength bispecif portfolio less clear point
encourag cr rate dlbcl patient post car-t treatment
addit data continu support potenti registr phii
studi remain focus safeti durabl higher dose cohort
overal view data posit support overal
launch enfortumab vedotin investor expect seattl
genet late-stag pipelin enfortumab vedotin potenti
commerci near term enfortumab vedotin ev jointli
develop astella cover shinichiro muraoka
evalu potenti treatment patient metastat urotheli
cancer muc base data first cohort patient dose
enfortumab vedotin fda assign pdufa date drug
march asset approv repres signific near term upsid
one product market would signal investor seattl
genet begin matur commercial-stag biotechnolog compani
addit ev appear superior efficaci compar
immunomed sacituzumab govitecan current
develop patient muc investor expect high believ
enfortumab vedotin prime growth especi given management experi
market assum commerci enfortumab vedotin
peak revenu sourc
much upsid tucatinib provid tucatinib orally-dos small
molecul tyrosin kinas inhibitor current develop
drug evalu treatment patient advanc metastat
breast cancer pivot phii neoadjuv breast cancer
set phii i-spi metastat colorect cancer phii
mountain approv believ tucatinib potenti take share
therapi market decemb management present detail
os data drug demonstr increas
increas os vs market tki nerlynx tykerb importantli
pfs/o advantag similar subpopul brain metastas
drug less sever gastrointestin side-effect vs competitor result
posit see tucatinib key line combin agent model
peak pos-adjust sale tucatinib management expect file nda
us eu
adcetri continu growth trajectori adcetri potent
present commerci product drug indic
varieti differ type lymphoma rang classic hodgkin lymphoma
non-hodgkin lymphoma specif subtyp therein drug
approv sinc approv use six differ
subtyp chl/nhl label expans addit increas market
share driven adcetri sale growth past expect trend
continu believ signific market opportun remain penetr
front line hodgkin lymphoma set investor larg price
adcetri potenti futur growth result adcetri revenu growth
repres key support factor valuat believ
adcetri revenu continu grow multi-prong strategi
includ label expans specif combin checkpoint inhibitor
earlier line therapi increas penetr currently-approv indic
geograph expans partnership takeda effort execut
strategi current underway form label expans studi increment
long-term safeti efficaci data confirmatori trial continu
collabor takeda develop adcetri ex-u footprint result
model out-year sale slightli consensu
surpris management develop small corrector molecul
antitrypsin defici aatd treatment therapi
develop target two aatd manifest liver lung diseas
developing/exist therapi target one aatd manifest
current evalu phii studi initi note
phii studi measur surrog endpoint level clinic
outcom eg highlight current augment
therapi approv base level management plan announc clinic data
key investor debat revolv around approv pathway
two potenti approv pathway tradit approv pathway
expect outcom wherein management requir conduct phiii studi
demonstr lead improv clinic endpoint
case calcul launch confer
peak risk-adjust sale note acceler approv
pathway upsid surpris wherein approv base surrog endpoint
name level scenario bull case calcul
launch note scenario approv criteria
in-line fda approv augment therapi current soc
approv base achiev plasma level um note recent
aatd workshop fda regul state willing engag
sponsor order identifi optim registration-en endpoint
pertin sponsor approach collect believ follow factor
could favor acceler approv offer upsid surpris high
unmet need given patient sever aatd increas
mortal high promis surround therapi target
aatd manifest potenti treat lung liver diseas fact
augment treatment target lung diseas
approv base level await first clinic data
management beat rais trikafta launch trikafta tripl combin therapi
cystic fibrosi cf approv fda oct month ahead
pdufa date trikafta highest efficaci among vertex cf drug
approv render cf patient popul elig treatment
vertex drug trikafta earli approv clear posit vertex gave
rise investor debat around whether management execut robust launch
exceed expect management state sale forc readi launch
anticip uptak limit noth capac cf
center recruit assess dose elig patient believ follow
factor hint robust execut potenti beat expect
year experi management work payer cf drug render payer
well awar vertex drug also high unmet need cf
recognit trikafta therapeut effect cf high unmet need fda
reflect earli approv fact previou vertex cf drug fulli
penetr label popul month management less
experienc cf arena reimburs agreement management
alreadi achiev countri includ challeng countri
england pave way trikafta reimburs look forward management
updat launch dynam
els pipelin could drive upsid beyond commerci product
focus cystic fibrosi aatd program management popul pipelin
addit program alreadi deliv promis clinic
data inhibitor small molecul pain manag
compound met primari endpoint proof-of-concept clinic studi
believ management like announc data sometim gene
edit therapi hemoglobinopathi collabor crispr cover
management recent announc data patient note
announc addit data data addit patient longer
follow-up consist data believ
support develop mediat
kidney diseas wherein phi studi healthi subject complet
management move follow-on molecul late-stag research
preclin level management develop gene therapi duchenn muscular
dystrophi myoton dystrophi type well cell-bas therapi
diabet overal vertex possess key pipelin asset present growth
opportun beyond cf drive multi-billion dollar peak sale potenti
sustain base busi biomarin focus rare diseas current
market therapi revenu guidanc importantli
market therapi includ enzym replac therapi mp
disord account total revenu competitor compani
sangamo also develop gene therapi
disord rais investor concern success gene therapi one-
time treatment could potenti render biomarin commerci product
vulner opinion gene therapi disord pose
immedi threat biomarin busi sustain follow reason
develop gene therapi disord current earli
stage even success like access market next
year thu see gene therapi threaten biomarin commerci
product near futur case gene therapi product ultim get
approv given risk profil like take mani year
heavili penetr market time gene therapi product take
market indic expect biomarin addit commerci
product valrox expect approv hema vosoritid expect
approv achondroplasia potenti initi registr
trial pku could confer signific revenu stream taken togeth
believ biomarin market product sustain next year
late-stag product provid option upsid potenti
approv risk valrox vosoritid valrox gene therapi hemophilia
submit ema approv acceler review process
expect file fda management state
acceler approv submiss fda requir patient achiev fviii level
iu/dl given achiev expect fda accept valrox
submiss acceler approv phii valrox demonstr suffici
fviii express accord calcul sustain year
note accord management calcul sustain
year slide howev phiii fviii level lower
phii median level iu/dl phiii vs iu/dl phii therebi rais
concern actual durabl fviii express management argu
differ like attribut time steroid administr
address shortcom remain total phiii trial
patient overal given high unmet need hemophilia believ valrox
approv vosoritid investig treatment achondroplasia
pivot phiii data expect vosoritid alreadi demonstr strong
efficaci toler phii studi note phiii management
success achiev annual growth given fact
current fda-approv treatment achondroplasia vosoritid
demonstr signific therapeut effect compar untreat subject
natur histori studi coupl clean safeti profil expect major
roadblock vosoritid approv
pku genetherapi success investig
gene therapi pku treatment management evalu
like registration-en phi/phii studi consist dose select dose
expans part current fda approv therapi pku kuvan
palynziq market biomarin demonstr lengthi experi
establish biomarin pku arena competit sever key
investig pku cell/gen therapi current clinic develop
includ cellular therapi rubiu phi gene therapi homolog phi/ii
therapi compris phenylalanine-catabol bacteria phi/ii
highli competit landscap pku conjunct uncertainti
surround gene therapi potenti gener key investor debat
regard likelihood success differenti factor believ
follow characterist could acceler develop
increas likelihood success promis preclin data show
treatment achiev phe normal pku mice within week last
least week management expertis development/commerci side
pku indic given management alreadi launch kuvan palynziq
combin potenti registration-en phi/phii studi enabl
efficient/expedit trial execut launch unlik pku therapi
target phe normal restrict diet management set therapeut goal
normal phe normal diet thu render superior
therapi success management experi gene therapi manufactur
especi built valrox develop along
fact phi/ii studi perform use commercial-grad materi
expedit timelin circumv common roadblock gene therapi
develop collect believ management set stage
success await first clinic data conclus assess
therapeut potenti commerci viabil
exhibit morgan stanley research vs consensu revenu ep estim
catalyst growth outlook
provid catalyst calendar note key mileston compani coverag
univers focu catalyst also provid data competitor
catalyst applic
phii part data expect treat cmt
luspatercept-april fda set pdufa date potenti
approv luspatercept md
vadadustat -toplin pivot data fom
present data phii broader dialysi patient
present top line data phiii
present top line data phiii
potenti japan approv treatment non-dialysi dialysis-depend ckd
 initi infront phii poc data ftd-pgrn patient
elamipretide- initi phiii data primari mitochondri myopathi pmm
ultomiri subq phiii data test subcutan qw administr pnh
ahu
onpattro project sale
givlaari project sale
lumasiran potenti approv illuminate-a nda file
inclisiran potenti approv medicin company/novarti nda
abp submit bla biosimilar rituximab
 mid phii readout nsclc updat statu
top-line data expect pivot trial apr-
azacitidin md
cohort gmg
transcon pth phii top-line data hypoparathyroid
file bla/maa ghd
phii data acomplish trial
first ind oncolog file
aducanumab file submit bla potenti fda panel potenti
tecfidera patent rule ptab district court case
rimegep top-line phiii result prevent treatment migrain
rimegep potenti fda approv acut set launch
valoctocogen roxaparvovec regulatori approv us eu
valoctocogen roxaparvovec mid- phii data updat
vg/kg dose updat fom vg/kg dose
updat vg/kg dose updat fom vg/kg dose
data phiii studi hemophilia
potenti approval/launch sever hemophilia acceler approv file
potenti launch achondroplasia
lentiglobin potenti us approv launch tdt
 potenti approv relapsed/refractori mm
potenti us approv launch tdt genotyp
potenti approv relapsed/refractori mm
potenti us/eu approv cald
potenti us eu filling/approv scd
earlier line approv launch
regulatori multipl potenti approv avapritinib
submit nda nsclc patient previous treat platinum-bas chemotherapi
pdufa pdgfra gist like month extent till may
submit nda advanc sm
submit nda ret-mut mtc previous treat approv multi-kinas inhibitor
file ind indol sm
submit nda gist
acut safeti data phi trial
musk-caart confirm target engag initi
acut safeti data phi trial
irb approv phi trial initi
confirm target engag initi ind enabl studi
valid manufactur support clinic program
phi primari safeti endpoint month post infus
omecamtiv phiii interim data efficaci expect
galactic-hf trial omecamtiv mecarbil manag base case
studi continu studi could potenti stop would
signific impact share
 engag data alzheim diseas al
viaskin peanut august fda target action date viaskin peanut
three-year follow-up data phiii pepit program
action date viaskin peanut bla
submiss viaskin peanut ema
earli begin patient dose phi/ii studi
begin patient dose phi/ii studi
provid updat nk cell program
tazemetostat pdufa es
 initi data oncolog indic
 late phii interim data psoriasi
phib data atop dermat new formul
phib data atop dermat new formul
phi/ii data mss colorect carcinoma relaps cancer
phiia interim data psoriasi enter capsul new formul
cabozantinib- earli phiii data expect combin studi
cabozantinib nivolumab rcc
magrolimab phib data studi magrolimab avelumab ovarian
magrolimab phib data studi magrolimab cetuximab colorect
magrolimab report interim efficaci data pivot phii
magrolimab rituximab dlbcl
losmapimod readout proof concept phiib studi fshd
losmapimod -type-c meet fda discuss whether biomark
use surrog endpoint
readout proof concept phiib studi fshd
readout open label phii studi fshd
type-c meet fda discuss whether biomark
use surrog endpoint
ind file sickl cell diseas
ind file beta thalassemia
filgotinib- anticip launch eu japan ra
glpg top line data toledo disclosur
glpg top-line phiib data osteoarthr roccella
teprotumumab pdufa date potenti approv launch
tisotumab vedotin pivot phii readout tisotumab vedotin cervic
darzalex may anticip pdufa darzalex subcutan
darzalex phiii readout daratumumb al amyloidosi andromeda
filgotinib anticip launch filgotinib ra eu japan
 fda pdufa date bla r/r mcl
initi pivot studi inclacumab
epidiolex project sale
epidoilex mid potenti snda approv
launch expect franc germani uk spain itali
safeti studi patient expect commenc
singl pivot phiii multipl sclerosi spastic
ind open pt ol autism studi recruit begin
submit snda
snda decis
jan fda accept bla resubmiss mtnbc
 phiii confirmatori studi ascent top-lin data
 potenti approv bla resubmiss acceler
ruxolitinib cream phiii data atop dermat
data studi itacitinib steroid-nav acut gvhd sn agvhd
nda submiss capmatinib non-smal cell lung cancer nsclc
pdufa date fgfr inhibitor pemigatinib cca
data studi jakafi steroid-refractori chronic gvhd sr cgvhd
initi data parsaclisib follicular lymphoma fl mantl cell lymphoma mcl margin zone
initi data msi-high endometri cancer anal cancer merkel cell
data phiii program ruxolitinib cream atop dermat
data phiii program ruxolitinib cream vitiligo
data studi itacitinib steroid-nav chronic gvhd sn cgvhd
 readout non-cyst fibrosi bronchiectasi
arikayc ali anticip file arikayc japan
arikayc ali anticip launch arikayc eu
 readout patient pulmonari arteri
ionis-httrx- phii ole data huntington
phii subtyp ib
 phiii data persist gerd
 phii data urea cycl disord ucd
clinic data data non-ind studi patient colon multi-drug resist pathogen
clinic data data phii clinic studi ucd
initi non-ind studi
feb present complet phib data angiogenesi meet
margituximab nda file phiii sophia trial
 phi studi test cmv interim
 safeti poc biomark data mad phi/ii studi
pediatr patient mma
phiii data expect explor studi
mavacamten patient obstruct hcm
contepo potenti approv cuti subsequ re-fil
european cta file evalu patient metastat melanoma
orilissa could approv uterin fibroid
opicapone-april fda set pdufa date potenti
approv opicapon parkinson
phii proof-of-concept data expect solid tumor
addit biomark data phi portion expect
initi single-arm urgent surgeri studi andexxa
initi registr studi peripher t-cell lymphoma
initi data phi/ii studi type gaucher
biomark data expect phi/ii studi
parkinson patient gba mutat
top line data phiii wearabl studi abalo-patch
dupixent- phii result copd ad
libtayo phiii result nsclc
 initi phiib trial wet
ind file phii studi diabet retinopathi
ind applic submiss
initi phiib trial wet
updat program clinic trial
setmelanotid pivot data bb alstrm syndrom
 initi data part pku
initi data part pku
submit ind addit rct product candid
micro-dystrophin initi confirmatori studi dmd
enfortumab vedotin enfortumab vedotin advanc metastat uc
tisotumab vedotin pivot phii readout tisotumab vedotin cervic
 final os analysi pivot trial hr breast cancer
phi/ii data expect patient cohort studi
around
data phib trial oa knee
file ind ophthalmolog potenti pulmonari indic
data phib trial oa knee
data phii trial oa knee
 initi efficaci data studi solid tumor
patient enrol statu preliminari safeti data phi studi
data cohort phi studi r/r nhl
initi efficaci data studi solid tumor
ind file
 data phii studi aatd patient zz mutat
-addit data hemoglobinopathi
data phii studi aatd patient zz mutat
initi poc phii studi focal segment glomerulosclerosi fsg
addit data hemoglobinopathi
inebilizumab- june fda set pdufa date potenti
approv inebilizumab nmosd
voyag expect file ind huntington
enrol first patient trial
dasiglucagon- earli nda file chi
dasiglucagon- phiii data chi children age month year
growth fairli steadi
inflect biotech revenu overal revenu flatten
primarili driven decreas gilead revenu see exhibit project
growth remain roughli mid-singl digit gilead car-t program see
provid support provid plot key data top biotech
exhibit total revenu top
exhibit total revenu top
gilead uniqu revenu profil due blockbust perform hcv
market gilead revenu remov analysi total revenu
number top biotech compani achiev consist steadi growth
exhibit y/i revenu growth rate
exhibit y/i revenu growth rate
top compani gilead
gilead remov analysi spike also disappear
downward trend revenu growth rate begin
oper margin top biotech steadili improv base
exhibit averag oper margin top biotech
exhibit averag oper margin top biotech
gilead remov analysi signific chang oper
margin also look total ep larg biotech compani see
total ep compani steadili increas exclus
gilead slightli smoothen increas ep effect seem minor
exhibit total ep top biotech
exhibit total ep top biotech gilead
also plot ep growth top top biotech former ep
growth model appear remain broadli constant
latter ep growth appear decreas recov gilead
remov ep growth analysi spike elimin
exhibit mean y/i ep growth top
gilead top biotech
exhibit mean y/i ep growth top
gilead top biotech gilead
healthcar slow time high
focus later stage market asset half deal asset yet
phiii biopharma activ number increas
 activ still occur late stage
market asset half deal asset yet phiii
focus larg biopharma combin phii asset
histor one-off event high activ larg last
year larger period high activ becom frequent
upward trend healthcar time continu show sign stabil
exhibit valu complet us healthcar transact
sinc downward trend overal size healthcar
combin somewhat stabil valu complet deal indic
trend toward execut larger deal
exhibit volum complet us healthcar transact
despit high variabl recent stabil size healthcar
 transact proport total transact
exhibit size healthcar transact total deal
earli onward continu upward trend healthcar
 deal initi percentag fulli execut current level
observ sinc
exhibit percent healthcar deal complet
care offer intens recent climb rapidli peak level recent year
howev recent observ volum revers around median
chart display price chang occur revenu
gener compani within coverag
exhibit price chang summari
price-to-earnings basi biotech tick last year all-tim low still trade
discount healthcar compani
exhibit price-to-earnings ratio market healthcar
exhibit rel price-to-earnings healthcar biotech market
ev/ebitda basi healthcar pharma trade line
market recov last year trade along market
rel basi ev/ebitda valuat biotech recent revers time
exhibit ev/ebitda market healthcar
exhibit rel ev/ebitda healthcar biotech market
dramat improv yield last year yield
current premium pharma healthcar overal market sector
abl larg hold out-performance sinc may late-
cycl trend manag team move invest new product cycl posit
biotech well invest cycl
exhibit yield market healthcar pharma
basi investor paid premium biotech growth rel
pharma biotech valu remain fairli steadi sinc occasion
volatil pharma valuat steadi posit
exhibit median valu pharma
biotech valuat highli depend larg termin valu driver
result biotech valuat highli sensit chang discount rate us
equiti market whole neg exposur steepen yield curv
exhibit pharma yield curv level sensit
previou high set last year ipo volum start trend still remain
high compar histor level follow-on also decreas time high
exhibit histor number biotech ipo follow-on
exhibit valu biotech ipo follow-on
year year return biotech ipo larg diminish slight
uptick late ipo basket first neg return last
longer month extend ipo
basket remain posit part basket
mostli flat interestingli ipo basket come significantli
last year outpac basket
exhibit return biotech ipo
thomson reuter morgan stanley research note chart trail day averag delist compani exclud
earli spike return ipo relat stock price perform
diminish return mani basket occur
basket impact later half year sever basket seen
increas return basket reach best return yet driven
acquisit ra cover out-performance reata
cover individu perform mix
return improv due out-performance karuna
therapeut cover
exhibit return biotech ipo basket
thomson reuter morgan stanley research note chart trail day averag delist compani exclud
ipo premium versu last privat round increas
signific declin investor demand greater
exhibit ipo step-up healthcar crossov round
summar market trend market share evolut key market
us market gcsf therapi decreas year-over-year
bit uptick base ytd im prescript data predict declin
albeit less intens year past
exhibit gcsf y/i market size decreas
exhibit gcsf market share evolut
im data indic size us esa market continu declin
follow modest growth project slight
reduct overal size esa market note epogen lost
signific share y/i aranesp procrit recently-approv biosimilar retacrit
note im data track roch mircera present signific
competit epogen freseniu medic north america oper larg
number outpati dialysi center us
exhibit esa y/i market growth/decreas
exhibit esa market share evolut
im data indic inject anti-tnf market grown steadili year-over-
year estim growth expect im data indic
enbrel gradual lost share humira cimzia maintain rel
consist share us prescript
exhibit anti-tnf y/i market growth/decreas
exhibit anti-tnf market share evolut
im prescript data indic hiv market experienc volatil size
follow declin project
continu trend end base prescript gilead share
us hiv market grown steadili
prescript share evolut gilead hiv therapi provid
exhibit hiv y/i market growth/decreas
exhibit market share prescript gilead hiv therapi
approv sovaldi harvoni substanti increas size hcv daa
market shown therapeut recent lose share
epclusa mavyret im prescript trend also demonstr sovaldi
harvoni rapid uptak provid bolu hcv market moder
exhibit hcv y/i market growth/decreas
exhibit hcv prescript market share evolut daa market
im prescript data indic ms market recent experienc y/i
contract expect trend continu estim
reduct overal market size continu maintain
exhibit ms y/i market growth
exhibit prescript share evolut select ms therapi
under-perform broader market ytd btk vs
 compar outsid biotech sector
outperform compar pharma gener healthcar wherea
btk slightli under-perform drg iyh
factor driven posit biotech sentiment fade polit nois
regard measur curb drug price higher level sector vs
investor expect go year
exhibit perform drg vs btk gener healthcar ytd
exhibit perform iyh vs btk ytd
exhibit perform btk vs ytd
better understand foreign exchang movement effect mani compani
coverag univers analyz trend dollar versu euro yen
calcul averag fx impact global revenu rel
usd stronger euro exhibit weaker yen exhibit
simpl fx explan weaker usd benefit ex-u sale respect
region stronger usd yoy impact ex-u sale neg respect
full phase ii compani competitor readout
tabl show phii phiii compani competitor readout expect
base inform clinicaltri gov whose primari complet date
darker row competitor data lighter row covered-compani
anemia subject dd-ckd
anemia chronic kidney diseas
anemia chronic kidney diseas
hemophilia
relaps refractori multipl myeloma
relaps refractori multipl myeloma
relaps refractori multipl myeloma
relaps refractori multipl myeloma
relaps refractori multipl myeloma
relaps refractori multipl myeloma
solid tumor kra mutat
solid tumor kra mutat
relaps refractori multipl myeloma
solid tumor kra mutat
relaps refractori multipl myeloma
relaps refractori multipl myeloma
compani
compani
ret-alt non small cell lung cancer|medullari thyroid cancer|ret-alt papillari thyroid cancer|ret-alt colon cancer|ret-alt solid tumors|lung neoplasm|carcinoma non-small-cel lung|thyroid diseases|thyroid neoplasm|thyroid cancer papillary|carcinoma neuroendocrine|respiratori tract neoplasms|thorac neoplasms|neoplasm site|neoplasms|lung diseases|respiratori tract disease|carcinoma bronchogenic|bronchi neoplasms|endocrin diseases|endocrin gland neoplasm|head neck neoplasms|adenocarcinoma papillary|adenocarcinoma|carcinoma|neoplasm glandular epithelial|neoplasm histolog type|neuroendocrin tumors|neuroectoderm tumors|neoplasm germ cell embryonal|neoplasm nerv tissue|colon neoplasms|colorect neoplasms|intestin neoplasms|gastrointestin neoplasms|digest neoplasm|digest disease|gastrointestin disease|colon diseases|intestin diseas
neoplasms|melanoma|non small cell lung cancer nsclc |head neck squamou cell carcinoma hnscc |renal cell carcinoma rcc |urotheli neoplasm|hepatocellular carcinoma |microsatellit instability-high mismatch repair defici msi-h/dmmr |colorect cancer|gastroesophag junction adenocarcinoma|gastr cancer|cerv cancer
advanc metastat solid tumors|advanc metastat melanoma|advanc metastat head neck squamou cell carcinoma|advanc metastat cutan squamou cell carcinoma|advanc metastat merkel cell carcinoma
small cell lung cancer|non-smal cell lung cancer squamous|non-smal cell lung cancer non-squamous|head neck squamou cell carcinoma|esophag squamou cell carcinoma|gastr adenocarcinoma|gastroesophag junction adenocarcinoma
nsclc non small cell lung cancer|rcc renal cell cancer|pancreat cancer|urotheli cancer|head neck cancer|dlbcl diffus larg cell lymphoma|mss microsatellit stabl colon cancer|tnbc tripl neg breast cancer|melanoma
forti seven inc |california institut regen medicin cirm
avelumab combin talazoparib investig patient local advanc primari recurr metastat solid tumor
non small cell lung cancer nsclc |urotheli carcinoma uc |squamou cell carcinoma head neck scchn |metastat breast cancer mbc |castration-resist prostat cancer
pralsetinib metastat melanoma advanc solid tumor
advanc solid tumor metastat squamou cell carcinoma head neck
combin nivolumab|combin nivolumab ipilimumab
pralsetinib solid cancers|advanc solid cancer refractori
intrahepat cholangiocarcinoma|combin hepatocellular cholangiocarcinoma
solid tumor adult|head neck cancer|non small cell lung cancer|pancreat cancer|diffus larg cell lymphoma
local advanc metastat solid tumor
local advanc metastat solid tumor
local advanc metastat solid tumor
colorect neoplasms|carcinoma non-small-cel lung|exocrin pancreat cancer|carcinoma squamou cell head neck
phase advanc refractori solid tumours|phas part metastat breast cancer prostat cancer skin cancer
solid tumor adult|tripl neg breast cancer|head neck squamou cell carcinoma|non small cell lung cancer
advanc metastat solid tumor
urotheli carcinoma|ren cell carcinoma|non-smal cell lung cancer|castration-resist prostat cancer|tripl neg breast cancer|ovarian cancer|endometri cancer|hepatocellular carcinoma|gastr cancer|gastroesophag junction adenocarcinoma|colorect cancer|head neck cancer|differenti thyroid cancer|low esophag cancer
avelumab mg combin pemetrex carboplatin| avelumab mg combin gemcitabin cisplatin |avelumab mg combin pemetrexed/carboplatin|avelumab mg combin gemcitabine/cisplatin
pancreat ductal adenocarcinoma|colorect cancer|gastr cancer|squam cell carcinoma head neck|bon cancer|advanc cancer|recurr disease|metastat tumour
pharmacokinet zolbetuximab|gastr cancer|gastro-esophag junction gej cancer|pharmacokinet oxaliplatin|pharmacokinet fluorouracil bolu
non-smal cell lung cancer|smal cell lung cancer|urotheli carcinoma|head neck squamou cell carcinoma|merkel cell carcinoma|melanoma|ren cell carcinoma|gastr cancer|cerv cancer|hepatocellular carcinoma|microsatellit instability|mismatch repair deficiency|colorect cancer
breast gene gene posit gastric cancer|salivari gland cancer|salivari gland tumor|salivari gland carcinoma|salivari gland neoplasms|lung cancer|colo-rect cancer|rar diseases|solid tumor|recurr gastric cancer|recurr colon cancer|recurr breast cancer|head neck cancer|head neck carcinoma|bladd cancer|cerv cancer|liv cancer|bil duct cancer|urolog cancer|pancreat cancer|prost cancer|recurr prostat cancer|rect cancer|recurr ovarian carcinoma|recurr renal cell cancer|rect cancer stage ii|rect cancer stage i|rect cancer stage iii|skin cancer|mouth cancer|lip cancer stage i|tongu cancer|breast neoplasm malign primary|larynx cancer|tonsil cancer|pal cancer|mucoepidermoid carcinoma|primari periton carcinoma|mucin adenocarcinoma gastric|mucin breast cancer recurrent|cholangiocarcinoma
meshalkin research institut patholog circul phosphocreatin sodium tetrahydr
failur
failur
failur
isfahan univers medic sciences|n institut
medic research develop
nation institut age nia |nation institut
failur
failur
failur
failur
failur
infant formula ad synbiot
forti seven inc |the leukemia lymphoma societi
curi inc |the leukemia lymphoma societi fimepinostat|rituximab|venetoclax|bendamustin tazemetostat
relaps refractori b-cell non-hodgkin lymphoma
solid tumor adult|head neck cancer|non small cell lung cancer|pancreat cancer|diffus larg cell lymphoma
nsclc non small cell lung cancer|rcc renal cell cancer|pancreat cancer|urotheli cancer|head neck cancer|dlbcl diffus larg cell lymphoma|mss microsatellit stabl colon cancer|tnbc tripl neg breast cancer|melanoma
compani
pfizer| lilli compani
compani
cetuximab
head neck cancer
head neck cancer
sapacitabine/decitabin azacitidin
olutasidenib/azacitidin azacitidin
tamibarotene/azacitidin azacitidin
md dlbcl
pfizer| lilli compani
glucosamin sulphat
princ wale hospit shatin hong kong
combin nivolumab
compani
complex perian fistula adult patient crohn diseas
forti seven inc |the leukemia lymphoma societi
curi inc |the leukemia lymphoma societi
spastic due multipl sclerosi
ga depot monthli
angiofibroma face|tuber sclerosi
company|incyt corpor
company|incyt corpor
compani
moder sever ulcer coliti
eryaspas l-asparaginas encapsul
sacituzumab govitecanloc advanc primari recurr metastat solid tumor
genet astella sanofi
combin nivolumab
sanot research develop corp
inc wholli own subsidiari
hanmi pharmaceut compani ezetimibeionis-agt-lrx
compani
mild moder alzheim diseas
mild moder alzheim diseas
mild moder alzheim diseas
nohla inc |fred hutchinson cancer research center|n cancer institut nci |nation heart lung blood institut nhlbi
forti seven inc |california institut regen medicin cirm
aza
sapacitabin decitabin part complet sapacitabin venetoclax part recruit
avelumab mg combin pemetrex carboplatin| avelumab mg combin gemcitabin cisplatin avelumab mg combin pemetrexed/carboplatin| avelumab mg combin gemcitabine/cisplatin
combin nivolumab| combin nivolumab ipilimumab
matina biopharma nanotechnolog inc |univers cologne|th clinic trial centr cologn
compani
intercept blood system red blood
tumor macrophag
tumor macrophag
pd implant ranibizumab mg/ml
tislelizumab cisplatin carboplatin pemetrex
gefitinib
sever osteoarthr knee
polymyositis|dermatomyositis|autoimmun necrot myopathy|overlap myositis|juvenil myositi
ret-alt non small cell lung cancer|medullari thyroid cancer|ret-alt papillari thyroid cancer|ret-alt colon cancer|ret-alt solid tumors|lung neoplasm|carcinoma non-small-cel lung|thyroid diseases|thyroid neoplasm|thyroid cancer papillary|carcinoma neuroendocrine|respiratori tract neoplasms|thorac neoplasms|neoplasm site|neoplasms|lung diseases|respiratori tract disease|carcinoma bronchogenic|bronchi neoplasms|endocrin diseases|endocrin gland neoplasm|head neck neoplasms|adenocarcinoma papillary|adenocarcinoma|carcinoma|neoplasm glandular epithelial|neoplasm histolog type|neuroendocrin tumors|neuroectoderm tumors|neoplasm germ cell embryonal|neoplasm nerv tissue|colon neoplasms|colorect neoplasms|intestin neoplasms|gastrointestin neoplasms|digest neoplasm|digest disease|gastrointestin disease|colon diseases|intestin diseas
urotheli carcinoma|ren cell carcinoma|non-smal cell lung cancer|castration-resist prostat cancer|tripl neg breast cancer|ovarian cancer|endometri cancer|hepatocellular carcinoma|gastr cancer|gastroesophag junction adenocarcinoma|colorect cancer|head neck cancer|differenti thyroid cancer|low esophag cancer
non small cell lung cancer nsclc |urotheli carcinoma uc |squamou cell carcinoma head neck scchn |metastat breast cancer mbc |castration-resist prostat cancer
moder sever atop dermat
local advanc metastat nsclc
squamou cell carcinoma posit
avelumab combin talazoparib investig patient local advanc primari recurr metastat solid tumor
solid tumor adult|head neck cancer|non small cell lung cancer|pancreat cancer|diffus larg cell lymphoma
solid tumor adult|tripl neg breast cancer|head neck squamou cell carcinoma|non small cell lung cancer
osteoarthr knee|pain
compani
canadian research educ arthritis|abbvieadalimumab
grapipr pembrolizumab
combin nivolumab
sichuan bio-chem scienc technolog develop co ltd|cancer institut hospit chines academi medic scienc
small cell lung cancer|non-smal cell lung cancer squamous|non-smal cell lung cancer non-squamous|head neck squamou cell carcinoma|esophag squamou cell carcinoma|gastr adenocarcinoma|gastroesophag junction adenocarcinoma
non-smal cell lung cancer|smal cell lung cancer|urotheli carcinoma|head neck squamou cell carcinoma|merkel cell carcinoma|melanoma|ren cell carcinoma|gastr cancer|cerv cancer|hepatocellular carcinoma|microsatellit instability|mismatch repair deficiency|colorect cancer
neoplasms|melanoma|non small cell lung cancer nsclc |head neck squamou cell carcinoma hnscc |renal cell carcinoma rcc |urotheli neoplasm|hepatocellular carcinoma |microsatellit instability-high mismatch repair defici msi-h/dmmr |colorect cancer|gastroesophag junction adenocarcinoma|gastr cancer|cerv cancer
reveragen biopharma inc |univers pittsburgh|coop neuromuscular research group
reveragen biopharma inc |european union|coop neuromuscular research group|newcastl university|univers pittsburgh
ns pharma inc |nippon shinyaku co ltd |cooper neuromuscular research group|therapeut research neuromuscular disord solut trind
pertuzumab trastuzumab fdc sc| pertuzumab iv| trastuzumab iv
astella sanofi
atezolizumab engin antibody| docetaxel
tislelizumab cisplatin carboplatin pemetrexed| cisplatin carboplatin pemetrex
pembrolizumab| paclitaxel| nab-paclitaxel| carboplatin| salin placebo pembrolizumab
erlotinib gefitinib
non small cell lung cancer nsclc |urotheli carcinoma uc |squamou cell carcinoma head neck scchn |metastat breast cancer mbc |castration-resist prostat cancer
atezolizumab engin antibodi
icotinib| wbrt sr
avelumab combin talazoparib investig patient local advanc primari recurr metastat solid tumor
avelumab mg combin pemetrex carboplatin| avelumab mg combin gemcitabin cisplatin avelumab mg combin pemetrexed/carboplatin| avelumab mg combin gemcitabine/cisplatin
solid tumor adult|tripl neg breast cancer|head neck squamou cell carcinoma|non small cell lung cancer
sichuan bio-chem scienc technolog develop co ltd|cancer institut hospit chines academi medic scienc
opdivo inject product keytruda inject product|combin product trans-arteri tirapazamin embol
nsclc non small cell lung cancer|rcc renal cell cancer|pancreat cancer|urotheli cancer|head neck cancer|dlbcl diffus larg cell lymphoma|mss microsatellit stabl colon cancer|tnbc tripl neg breast cancer|melanoma
small cell lung cancer|non-smal cell lung cancer squamous|non-smal cell lung cancer non-squamous|head neck squamou cell carcinoma|esophag squamou cell carcinoma|gastr adenocarcinoma|gastroesophag junction adenocarcinoma
anewpharma|renmin hospit wuhan univers
osteoarthr knee|pain
boehring ingelheim| lilli compani
boehring ingelheim| lilli compani
brigham women hospital|bristol-my squibb
boehring ingelheim| lilli compani
boehring ingelheim| lilli compani
compani
equal-weight rate base
expect limit upsid near-term
posit luspatercept
assum high probabl approv
preliminari phase part data
preliminari sotatercept data phase
pulsar studi patient pah
data non-transfus depend beta-th
risk achiev price
data better-than-expect luspatercept
downsid risk neg cmt data
luspatercept approv md
pt deriv dcf use
discount rate assum po rs md transfusion-
depend beta-th addit assum po
first line md non-transfusion-depend beta-th mf
posit data mf non-transfus depend beta-th bull case
assum higher probabl success po non-transfus
depend beta-th mf
luspatercept launch reach peak ww revenu
first two indic base case assumpt describ price
target methodolog
luspatercept launch slower-than-expect bear case assum peak
us market share md beta-th respect
addit assum luspatercept success follow-on indic
vadadustat drive akebia share
vadadustat drive akebia share
pt deriv dcf use discount rate
termin growth rate beyond valu akebia nephrolog
vadadustat exce expect allow therapi take addit share
epo regimen appli risk adjust
vadadustat launch drug profil allow success howev
ampl risk remain program lead risk adjust
vadadustat fail compani valu cash
equal-weight ahead phiii
major cardiac event mace data
see vadadustat therapi
benefit allow remov black
box respect cardiovascular event
might necessari success versu
infrastructur auryxia need show us
akebia merg keryx late
join auryxia vadadustat
compani ckd aresen auryxia
underperform sinc approv
hypophosphatemia though drug
recent expand label includ iron
defici anemia need see
drug perform gain confid
main valuat driver
perceiv clinic regulatori risk
vadadustat ckd dialysi set
risk achiev price
akebia upcom mace data unabl
show vadadustat safer esa
would lead substanti weak
auryxia continu under-perform
akebia might need rais addit fund
issu equiti
cost expens
product revenues/royalti
cash equival
prepaid expens current asset
properti equip net
defer revenu net current portion
accumul comprehens incom loss
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
prepaid expens asset
accru expens liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas market secur
sale matur market secur
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
chang equival
equival begin year
chang due restat
equival end year
market secur restrict end year
safeti efficaci data ftd-grn drive risk/reward
safeti efficaci data ftd-grn
pt deriv dcf use discount
rate termin growth rate revenu driver model
current model
separ given earli stage develop
commerci strong uptak bull
case valu product launch
begin respect gener
sale
success commerci base
case valu product launch
begin respect gener
risk-adjust sale
fail unabl commerci trade cash
overweight thesi base
success commerci
design treat well defin
genet diseas measur biomark
compar neurodegen
probabl success
phi trial healthi volunt
demonstr target engag
provid confid impact genet
phib data ftd-pgrn
demonstr safeti efficaci expect
phii data ftd-pgrn patient also
demonstr clinic activ expect
demonstr efficaci
alzheim diseas expect
risk achiev price
signal would like caus investor
question valu
reduc efficaci ftd
delay timelin posit data
competitor could weigh
market share especi competitor data
arriv new indic prior pivot
effect treat
ultomiri share convers soliris/strensiq/kanuma sale growth drive
ultomiri share convers soliris/strensiq/kanuma sale growth drive
equal-weight believ
current valuat impli manag
unabl grow busi
overlook share shift potenti
ultomiri even conserv scenario
assum ultomiri achiev solid
profil assum either market share
price pressur year
assum strensiq achiev
meaning sale see modest sale
key revenu driver model
continu ahu pnh sale growth
franchis coupl growth
soliri mg success share shift
risk achiev price
soliri pnh ahu mg growth could fail
meet expect
strensiq and/or kanuma fail captur
share convers soliri ultomiri
project
could potenti bad
behavior identifi commerci
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model pnh sale ahu sale mg sale nmo sale strensiq
sale kanuma sale incorpor cash cost stock
diagnost algorithm drive sustain pnh ahu mg penetr
ultomiri succe signific share convers bull case assum
soliri becom standard care pnh ahu nmo mg pnh
sale peak ww ahu sale peak
assum strensiq kanuma continu launch sale
respect
soliri meaning growth pnh ahu gmg ultomiri succe
modest share convers base case assum solid convers ultomiri
long-term durabl complement franchis assum gmg
nmo meaning contribut sale assum strensiq kanuma
continu launch sale respect
see soliri longev incorpor competit price pressur
soliri face signific competit strensiq kanuma achiev minim
sale bear case assum soliri fail gain label expans soliri
face signific headwind biosimilar proprietari competit
diversif strensiq kanuma minim
onpattro sale advanc pipelin drive valu
onpattro sale advanc pipelin drive valu
pt deriv dcf use discount rate
termin growth rate beyond valu alnylam advanc
attr platform highli success givlaari lumasiran achiev strong sale
fitusiran inclisiran launch bull scenario assum onpattro
follow-on highli success form attr
givlaari lumasiran launch sell well fitusiran inclisiran
abl success gain approv appli modest pipelin valu
drug includ cemdisiran
attr franchis drive valu givlaari launch lumasiran launch
onpattro strong launch attr la launch aln-
drive sale model aip revenu givlaari
begin lumasiran launch risk adjust
incorpor royalti inclisiran appli modest pipelin valu
onpattro launch modest sale givlaari launch
overweight alnylam
believ mani risk challeng
alnylam give way
commerci growth expect
investor focu onpattro launch
exceed expect view
expect givlaari launch
lumasiran
view alnylam rnai platform
high potenti valu consid
rnai simpler demonstr
preclin proof concept
technolog alnylam larg pipelin
beyond ttr therapi offer potenti
substanti downstream valu
continu ramp onpattro
initi ramp givlaari well
clinical/regulatori updat lumasiran
inclisiran fitusiran
risk achiev price
pipelin failur proprietari
rnai therapi could lead substanti
chang share valu
neg safeti and/or efficaci data
therapeut program
clinic data competit program
suggest disadvantag drug
million per share basi indic
net revenu collabor
cost expens
product revenu royalti
million per share basi indic
equival
prepaid expens current asset
properti equip net
defer revenu net current portion
total liabil sharehold equiti
million per share basi indic
adjust reconcil net loss net cash use oper activ
depreci amort
chang oper asset liabil
pre-paid expens asset
accru expens
purchas properti plant equip
purchas market secur
sale matur market secur
increas reduct restrict
payment asset acquisit
net use invest activ
proce exercis stock option equiti
proce issuanc common stock
proce issuanc debt
net provid financ activ
chang equival
equival begin year
equival end year
market secur end year
biosimilar competit pipelin contribut drive risk-reward
biosimilar competit pipelin contribut drive risk-reward
overweight amgen believ
upsid pipelin recent
launch help reduc long-term risk
compani current base busi face
signific in-organ opportun growth
stabl base even biosimilar
believ protect key franchis
biosimilar competit near-term
long-term forecast gradual share
shift biosimilar versu cliff key
product neulasta enbrel
project period
divers pipelin begin
appreci gener posit
late-stag data key pipelin compound
earli aimovig launch migrain
appear encourag also
develop portfolio biosimilar
molecul believ take share
also watch matur
certain early-stag oncolog program
shown progress recent month
support global expans commerci
continu launch perform aimovig
erenumab migrain approv launch
biosimilar molecul
advanc early-stag
biosimilar entrant key legaci product
enbrel neulasta enbrel price power
potenti launch pipelin product
tezepelumab
risk achiev price
failur late-stag pipelin
lack margin expans
deriv pt discount cash flow dcf analysi
use wacc termin growth rate post
bear case main revenu driver model
eros base busi due biosimilar matur
lower biosimilar impact coupl outsiz revenu pipelin
assum pipelin sale tezepelumab peak
biosimilar revenu aimovig sale
sale modest line penetr
kyproli peak sale enbrel long-term patent hold
biosimilar enter market minim impact biosimilar
expos product biosimilar neulasta take total neulasta share
us biosimilar impact similar trend europ modest result
pipelin assum pipelin sale tezepelumab
peak biosimilar revenu aimovig sale
sale modest line
penetr kyproli peak sale enbrel
biosimilar start take share modest impact biosimilar
expos product biosimilar neulasta take total neulasta share
assum assum pipelin failur tezepelumab
line penetr kyproli relapsed/refractori market
peak sale declin y/i thereaft notabl impact biosimilar
expos product biosimilar neulasta take total neulasta share
biosimilar take total share
aimovig fail achiev signific market share migrain market
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak us
market share md md
post-transpl mainten mutant aml
adjust use probabl success po
higher po md assum higher po md mds/aml
post-transpl mainten r/r aml follow posit data
base case assumpt describ price target methodolog
platform reactiv mutant fail aprea unabl advanc
product candid trade cash value-per-share
equal-weight aprea
develop cancer therapi reactiv
mutant posit
compani believ share fulli
valu follow strong perform
sinc ipo result remain
sidelin look better entri point
ahead phase data
date phase data two studi
indic improv respons rate apr-
azacitidin histor azacitidin
md aml patient
compani focus initi md
aml evid
could effect treat solid tumor
upcom catalyst
begin phase
final data french phase
top-lin data phase md
risk achiev price
lack statist signific improv
azacitidin azacitidin
phase md
lack advanc early-stag
potenti litig patent
competit mds/aml
safeti efficaci data mg itp pv drive risk/reward
safeti efficaci data mg itp pv
pt deriv dcf use
discount rate termin growth rate revenu driver
model
commerci strong uptak bull case
valu risk adjust vari
product launch begin
respect gener sale
argenx success commerci base
case valu mg itp pv aml ctcl risk adjust vari
product launch begin
respect gener sale
fail argenx unabl commerci argx trade
overweight thesi base
success commerci
sever compani develop anti-
fcrn antibodi treatment
autoimmun diseas mani compani
report safeti and/or reduc efficaci
compar
design uniqu ph-
depend bind profil extend
therapeut durabl fewer report
advers event compar compet anti-
diseas indic demonstr
efficaci safeti
demonstr clinic
activ aml
phiii data gmg demonstr
differenti safeti efficaci
phii data pv itp also
top-line phiii data gmg expect
demonstr efficaci aml
risk achiev price
signal would like caus investor
question differenti valu
reduc efficaci
delay timelin posit data
competitor could weight
market share especi competitor data
arriv new indic prior pivot
effect treat
refractori aml patient compar
standard care
transcon hgh launch primari near-term opportun pipelin drive
transcon hgh launch primari near-term opportun pipelin drive
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model transcon hgh pth
deeper penetr transcon hgh pth adopt
transcon commerci product driven differenti risk-benefit profil
trancon hgh strong grower current project launch
therapi risk-adjust revenu reach assign
risk adjust given posit phiii data date pediatr larg drive
valuat predict drug gain use adult assum
transcon pth would launch
transcon pth fail launch hgh modest penetr clinic
failur result revenu pth hgh gain modest
transcon hgh could game changer
growth hormon market drug like
approv growth hormon defici
data date show posit result
two phiii studi nave height
trial pre-treat flight trial patient
bla transcon hgh track
submit long act hgh
welcom addit prescrib
patient allow ascendi
prescript ramp quickli project
opportun transcon pth replac
therapi treatment
hypoparathyroid could potenti
establish infusion-lik profil
long-act mechan incorpor
transcon technolog allow drug
address root caus diseas
current model launch transcon
manag note potenti
expand growth disord
provid opportun leverag
potenti synergi within platform plan
also made move oncolog
overal mechan combin benefit
prodrug predict releas
technolog model launch
primari driver ascendi
success pipelin candid increas
investor confid transcon platform
contribut greater overal valu
risk achiev price
clinic failur transcon pth
due lack efficaci emerg safeti
investor lose confid platform
cost expens
product revenues/royalti
revenu
net loss attribut common stockhold
oper expens
cash equival
properti equip net
invest associ
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
revers non-cash consider regard revenu
revers share profit/ loss associ
revers financ incom
revers financ expens
revers tax charg
chang oper asset liabil
flow gener from/ use oper
net provid use oper activ
flow invest activ
acquisit properti plant equip
net use invest activ
flow financ activ
proce exercis stock option equiti
capit increas
proce lt debt
effect fx translat
chang equival
equival begin year
equival end year
attract lentivir gene therapi platform drive valu
attract lentivir gene therapi platform drive valu
gene therapi compani
develop lentivir therapi lysosom
compani lead therapi
fabri diseas alreadi clinic data
human suggest therapi
could potenti cur derisk
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model risk adjust sale fabri diseas gaucher
diseas market well underli gene therapi platform valu
steeper ramp fabri gaucher scenario assum first revenu avr-rd-
reach peak appli risk adjust
launch reach peak risk
adjust includ modest peak adjust sale pomp cystinosi
fabri gaucher drive valu scenario assum first revenu
reach peak appli risk adjust avr-
launch reach peak risk
program fail valu cash
establish market alreadi identifi
popul also regulatori path well
establish make diseas less riski
rare diseas opportun
program earliest
potenti approv primari driver
valuat gaucher
diseas also key driver
risk achiev price
poor clinic data neg impact
street view specif pipelin
product gene therapi whole would
detriment share valu
lsd establish market
standard care product
like higher bar success
compet technolog gene
competit risk long haul
cost expens
good sold
net incom common sharehold
prepaid expens current asset
properti equip net
defer revenu net current p\ortion
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
prepaid expens asset
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas market secur
sale matur market secur
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
effect exchang rate
chang equival
equival begin year
equival end year
market secur end year
spinraza tecfidera ocrevu pipelin drive risk-reward
spinraza tecfidera ocrevu pipelin drive risk-reward
ocrevu pipelin
tecfidera reach higher market share limit impact biosimilar
signific margin expans lower discount pipelin asset
assum peak tecfidera sale gener
limit declin plegridy/avonex franchis
continu tysabri growth peak sale aducanumab
sale spinraza sale limit
impact rituxan/gazyva biosimilar
impact assum peak tecfidera sale gener
enter declin plegridy/avonex sale
stabl tysabri sale aducanumab sale
biosimilar rituxan impact start mainli off-set
impact pipelin assum global tecfidera sale
loss patent protect declin plegridy/avonex sale
greater competit signific neg price
environ biosimilar rituxan impact start
uw rate base view
risk base busi weigh
spinraza competit potenti
rituxan biosimilar overhang
tecfidera ipr expect
management track record transform
late-stag limit
expect signific capit
management chang strategi
risk achiev price
faster expect launch new
rimegep competitor migrain data glutam platform valid drive
rimegep competitor migrain data glutam platform valid drive
deriv pt discount cash flow dcf analysi
assum wacc termin growth rate post
main revenu driver model rimegep
episod migrain lesser extent glutam platform
robust rimegep uptak episod migrain commerci
chronic migrain strong share addit neurolog indic
glutam platform net product sale driven sale
rimegep aggreg cgrp
platform ex-u sale aggreg sale trigriluzol bhv-
 ex-u
strong share rimegep episod migrain modest share
addit neurolog indic glutam platform
net product sale driven sale rimegep
ex-u commerci commerci
chronic migrain aggreg sale trigriluzol bhv-
 commerci ex-u
pipelin failur rimegep glutam platform molecul fail
develop process compani trade cash value-per-share
equal-weight biohaven lead
larg unmet need acut treatment
migrain phiii data suggest product
could differenti emerg
competitor particularli safeti howev
believ valuat reflect posit
aspect thu see balanc
signific pipelin driver troriluzol bhv-
gener encourag
data troriluzol achiev
statist signific result phii/iii
spinocerebellar ataxia sca program
result drug inabl differenti
placebo seem trial/ind specif
current see limit read
glutam program expect key
data glutam platform
rimegep file
commerci clariti
glutam data particularli troriluzol
risk achiev price
regulatori hurdl rimegep
poor safety/efficaci data
base busi brineura vosoritid bmn drive valu
base busi brineura vosoritid bmn drive valu
aldurazym pipelin vosoritid bmn greatest
extra strength pipelin assum expect growth base
busi drug pipelin vosoritid bmn becom even larger
driver valu
pipelin contribut assum base busi perform well come
year also pegvalias approv trifecta vosoritid bmn
 bmn launch model bmn
bmn
pipelin current approv drug assum drug
pipelin unabl gener satisfactori result gain market approv
bear scenario
leader orphan opportun biomarin
uniqu player core
compet orphan drug set apart
larg cap emphas market
target larger popul
strength base busi establish
valu base busi vimizin naglazym
kuvan aldurzym contribut
revenu given natur market outsid
competit unlik allow base
busi creat valuat backstop
deep pipelin offer plenti
opportun upsid biomarin deep
wide product pipelin multipl drug
potenti launch end
vosoritid bmn possibl
blockbust contribut upsid
pipelin opportun near-term focu
investor focu pipelin
opportun nearer-term launch
pegvalias pku well potenti
blockbust vosoritid achondroplasia
bmn gene therapi treatment
find patient drive sale
base busi base busi drug
still grow recent launch
vimizim still leg drive sale
biomarin abil steadili find new patient
grow revenu opportun
bmn hemophilia gene therapi
bmn could signific impact
valuat matur data becom
risk achiev price
neg updat key pipelin drug
highlight safeti efficaci risk
bmn failur phase
focu orphan asset price could
impact investor view base busi
pipelin upsid particularli impact
termin valu busi
expens manag particular
meet year oper margin target
car-t bcma sickl cell beta-thalassemia gene therapi drive risk/reward
car-t bcma sickl cell beta-thalassemia gene therapi drive risk/reward
signific sickl cell uptak bcma car-t high share relaps set
modest beta-thalassemia penetr assum larg portion
elig scd patient receiv gene therapi signific portion
new incid popul receiv therapi beta-thalassemia assum
row penetr assum strong launch penetr
front line patient
uptak beta-thalassemia us/eu strong bcma car-t uptak
line moder sickl cell penetr scd project peak ww sale
assum oral competit baselin factor organ damag
stroke etc may limit uptak gene therapi beta-thalassemia
assum penetr develop market scd price
lentiglobin fail make market assum scd
beta thal make market model cash-bas valu assum
launch
equal-weight
compani progress sickl cell diseas
reflect valuat see car-t
bcma program main upsid
believ initi data repres
proof-of-concept allow us valu
penetr sickl cell market
penetr beta-thalassemia
see initi bcma car-t data
strong highli valu segment
peak sale assum
maintain major share
competit compani
addit car-t data durabl
data earlier line therapi
addit data follow-up
lentiglobin beta-th scd studi
new clinic program either gene
therapi car-t gene edit
risk achiev price
potenti efficaci safeti concern
would inhibit manag team
bring market addit
indic earlier line
efficaci lentiglobin given
limit number patient potenti
variabl patient engraft diseas
sever patient respons
safeti lentiglobin given lack
long-term follow-up limit patient
licens royalti revenu
cost expens
sale
research develop
gener administr
licens revenu
chang fair valu conting consider
oper expens
non- adjust
gener administr
research develop
st invest
cash equival
prepaid expens current asset
properti equip net
non-curr asset restrict cash
accru expens current liabil
defer rent net current portion
conting consider net current portion
accumul comprehens incom loss
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
non-cash benefit releas incom tax valuat allow
depreci amort
remeasur conting consider
issuanc restrict common stock exchang consult servic non-employe
re-measur warrant
loss dispos equip
chang oper asset liabil
prepaid expens asset
accru expens liabil
net cash use oper activ
purchas properti equip
payment made tenant improv capit leas
purchas market secur
proce sale matur market secur
acquisit busi
net cash use invest activ
proce public offer common stock
proce issuanc convert prefer stock
repay nonrecours note collater restrict stock-
reimburs tenant improv capit leas
proce exercis stock option issuanc common stock
paid conting purchas price consider
net cash provid financ activ
effect exchang rate chang cash cash equival
net decreas increas cash cash equival
chang cash due restat
cash equival begin period
cash equival end period
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model avapritinib
deeper penetr avapritinib assum deeper penetr avapritinib
line therapi kit driven gist form sm well higher
expect
avapritinib launch assum avapritinib launch pdgfr
resist gist kit gist kit driven gist project
launch appli risk
assum avapritinib use pdgfr resist gist popul
avapritinib indic unapprov
avapritinib key valu driver
blueprint drug like approv
pdgfra exon mutant gist fourth-
line gist early-to-mid gist
potenti earli data system
appear promis though
competit dynam ret-
inhibitor could well impact
show tki highli
repres
underappreci opportun
diseas rel treatment
option current avail drug
fairli ineffect poorli toler
blueprint present earli dose rang
data show promis efficaci
primari driver blueprint
avapritinib kit pdgfr mutant gist
well sm
risk achiev price
clinic failur avapritinib
due lack efficaci emerg
earlier stage pipelin fail advanc
collabor yield viabl
cost expens
product revenues/royalti
net incom loss continu oper
cumul dividend convert prefer share
net loss attribut common stockhold
oper expens
cash equival
prepaid expens current asset
properti equip net
current portion defer revenu
accru expens current liabil
accumul comprehens incom loss
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas short-term invest
matur short-term invest
net use invest activ
flow financ activ
proce issuanc common stock
net proce issuanc convert prefer stock
proce lt debt
effect fx translat
chang equival
equival begin year
equival end year
market secur end year
efficaci phase studi drive risk/reward
efficaci phase studi drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth valu estim us/eu
risk-adjust peak revenu use
po mucos pv/mucocutan pv/musk mg
receiv acceler fda approv
respect similar therapi kymriah estim us/eu risk-adjust
peak revenu
program approv full phiii program musk-
caart receiv tradit fda approv
respect estim us/eu risk-adjust peak revenu
fail fail receiv regulatori approv impact
overal caart platform viabil trade cash value-per-share
believ cabaletta proprietari
platform yield analog efficaci
compar therapi circumv
believ promis
compound demonstr
favor efficaci safeti profil
preclin studi see upsid
potenti acceler approv phi
believ manag continu
identifi auto-immun diseas
caart technolog appli
demonstr favor safeti profil
low rate expect
vivo target engag confirm
preclin studi musk-caart
move compound clinic test
earli
demonstr favor efficaci profil
effici specif cell targeting/kil
expect
risk achiev price
question valu
overal platform
unexpect safeti signal
caart trial would like caus investor
regul question risk-benefit ratio
lower probabl success
delay timelin posit data
pt deriv dcf use
sale adjust revenu use probabl
success po om reldesemtiv al
reldesemtiv sma
greater market share bull case assum greater adopt
omecamtiv mecarbil reldesemtiv
om commerci begin base case assumpt
describ price target methodolog
product candid fail advanc unabl advanc
product candid trade cash value-per-share
equal-weight thesi base lack
signific clinic catalyst ahead
omecamtiv mecarbil phase data
cautiou reldesemtiv given data
sma al
efficaci galactic-hf
omecamtiv mecarbil phase data
risk achiev price
data omecamtiv mecarbil
stop interim overwhelmingli
posit efficaci faster-than-expect
advanc pipelin candid
phase data galactic-hf
termin earli futil follow
step viaskin peanut program drive risk/reward
step viaskin peanut program drive risk/reward
deriv pt dcf base forecast dbv peanut
rate termin growth rate
modest share viaskin peanut commerci viaskin milk
viaskin egg viaskin peanut launch late gener peak ww sale
viaskin milk viaskin egg launch
respect obtain minim share achiev global
sale
modest uptak viaskin peanut commerci viaskin milk
viaskin egg viaskin peanut launch late gener
global sale contribut viaskin milk viaskin egg
given current regulatori statu viaskin peanut assum
probabl success
regulatori failur viaskin peanut commerci viaskin milk
and/or viaskin egg share trade cash value-per-share
equal-weight
gener mix phiii top line profil
manag subsequ pull back
bla viaskin peanut follow issu
highlight fda bla recent
resubmit accept fda
review believ regulatori
progress viaskin peanut bla
particularli anticip advisori
committe meet repres next key
step dbvt
viaskin milk viaskin egg repres
potenti upsid driver target
market high unmet need howev
given earli natur program
mix late-stag result viaskin peanut
egg milk program factor
bull case modest uptak
anticip advisori committe meet
discuss viaskin peanut bla
regulatori action competitor peanut
allergi product candid anticip
risk achiev price
lack support viaskin peanut
anticip fda advisori committe
greater expect competit
dbv nsdq dbvt
cost expens
sale
research develop
sell gener administr
non- adjust
research develop
gener administr
st invest
cash equival
inventori work progress
custom account receiv relat receiv
properti equip net
supplier account payabl relat payabl
premium relat share capit
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
depreci amort
expens relat share-bas payment
chang oper asset liabil
inventori work progress
net cash use oper activ
acquisit properti plant equip
acquisit intang asset
acquisit non-curr financi asset
cash flow relat invest transact
net cash use invest activ
increas condit advanc
decreas condit advanc
capit increas net transact cost
cash flow relat financ activ
net cash provid financ activ
effect exchang rate chang cash cash equival
net decreas increas cash cash equival
cash equival begin period
cash equival end period
program al alzheim parkinson bbb platform drive risk/reward
program al alzheim parkinson bbb platform drive risk/reward
pt base dcf base case forecast
parkinson al alzheim bbb platform
discount rate assum termin growth cash
greater alzheim market share success idiopath parkinson
bull case assum market share al market share
alzheim share total parkinson popul alzheim
risk-adjust us peak sale program
program
risk-adjust success alzheim good probabl success
mutat valu bbb program base case assum
market share al market share alzheim share
mutat parkinson us peak risk-adjust sale
program program bbb program repres
total peak revenu
alzheim success mutat parkinson valu bbb
program approv al alzheim approv
parkinson al program gener peak revenu
program gener peak revenu bbb program repres
peak revenu
overweight thesi base
confid manag abil
inflect product histor
difficult treat area neurosci
believ manag right
process inflect success use
genet target biomark target
engag parallel invest
improv success initi target
repres initi yardstick
opportun greatli expand treatment
engag inhibitor
engag data patient
program
potenti evid activ idiopath
initi preclin clinic data
demonstr util bbb
risk achiev price
preclin clinic safeti signal
program
inabl advanc
program clinic test due poor
efficaci concern safeti signal
failur bbb program greater
success competitor similar program
demonstr safe administr human ip resolut success
demonstr safe administr human ip resolut success
pt deriv dcf use discount rate
edita abl develop commerci therapi receiv widespread
uptak therapi launch us eu treat
cure address popul command premium
price gener peak ww sale edita also abl
realiz sale addit therapi car-t applic
non-malign hematolog dmd cf
therapi prove success addit therapi obtain modest
success therapi launch us eu treat
cure address popul gener peak ww
sale edita abl develop success therapi car-
hematolog dmd cf achiev sale
pipelin program fail edita abl commerci therapi
result valuat cash share
equal-weight
crispr gene edit platform
derisk oper standpoint
gear toward numer diseas
target howev deliveri long-term
safeti administ clinic relev
dose human need proven
edita system modular approach
may allow differenti
first diseas target
inherit retin dystrophi lower initi
risk prove gene edit work
human eye immun privileg
provid small contain area
suffici quantiti vector
overal see signific long-term
potenti edita remain equal-weight
initi therapi derisk clinic
progress program
program clinic
hematolog diseas genet diseas
lung liver
risk achiev price
ip outcom limit edita freedom
develop risk associ earli
natur pipelin timelin long
competitor could influenc investor
percept stock
pt deriv dcf use discount rate
termin growth rate beyond valu tazemetostat
tazemetostat approv ramp well assum tazemetostat launch es
fl strong uptak line therapi
tazemetostat launch strength later line assum tazemetostat
launch es fl assum bulk usag fl come
later line therapi
program fail compani valu cash
tazemetostat promis therapi
like approv epitheliod
sarcoma es earli follicular
lymphoma fl end year
drug broad applic
hematolog cancer potenti
applic solid tumor well
primari near term driver
regulatori clinic updat
tazemetostat fl es
risk achiev price
safeti issu previous
concern abat addit episod
could caus bubbl surfac
place pressur share
might suffici efficaci
compet current treatment
collabor fail result meaning
cost expens
product revenues/royalti
oper expens
equival
prepaid expens current asset
properti equip net
current portion defer revenu
accru expens current liabil
current portion capit leas oblig
capit leas oblig net current portion
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas short-term invest
proce sale short-term invest
net use invest activ
flow financ activ
proce public offer common stock net commiss
proce stock option exercis
issuanc share employe stock purchas plan
net proce issuanc convert prefer stock
proce lt debt
payment capit leas oblig
payment common stock offer cost
chang equival
equival begin year
equival end year
market secur end year
probabl success monoclon microbi therapi drive risk/reward
probabl success monoclon microbi therapi drive risk/reward
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model evelo lead monoclon microbi product candid
atop dermat psoriasi
signific share atop dermat psoriasi evelo inflamm
focus monoclon microbi launch atop dermat
psoriasi atop dermat evelo product gain share peak
patient control topic treatment psoriasi evelo obtain
share peak patient biolog oral respect assum
probabl success po atop dermat po psoriasi
estim peak pos-adjust revenu
modest share atop dermat psoriasi evelo product candid gain
share peak atop dermat patient control
topic treatment gain share peak psoriasi
patient biolog oral respect estim peak pos-adjust
revenu
program fail valu compani cash
treat system condit via gut-
bodi network nascent field evelo
signific clinic literatur recent
year support premis gut-bodi
network preclin data gener
date evelo lead product candid
inflamm oncolog encourag
initi phi data report recent lead
product candid demonstr
encourag efficaci signal psoriasi
scalabl sever potenti target
therapeut inher safe
deriv gut
phi data atop dermat
phi data atop dermat
phi/ii data oncolog
indic
phii interim data
psoriasi late
risk achiev price
earli setback microbiom
focus compani may weigh investor
futur readout replic
efficaci signal observ initi phi
unforeseen safeti signal
upcom
sale
research develop
gener administr
net loss comprehens loss
oper expens
non- adjust
research develop
gener administr
net incom attribut common stockhold
cash equival
prepaid expens current asset
properti equip net
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
chang fair valu warrant liabil
sale properti equip
chang oper asset liabil
prepaid expens current asset
accru expens current liabil
net cash use oper activ
acquir acquisit epiva
purchas properti equip invest
proce sale properti equip
net cash use invest activ
net proce issuanc convert prefer stock
proce issuanc long-term debt
repay long-term debt
proce exercis stock option common stock
chang stockhold payabl
net cash provid financ activ
restat chang restrict
net decreas increas cash cash equival
cash equival begin period
cash equival end period
pt deriv dcf use discount
rate model peak us market share translat
peak sale rcc assum peak us market share
translat peak sale
greater peak market share rcc bull case assum
peak us market share translat peak sale
addit assum peak us market share rcc share
translat peak sale rcc
expect gradual launch base case assumpt
describ price target methodolog
lower long-term market share rcc greater-than-expect
competit pressur beyond cabozantinib market share declin
patent expir rcc reach share rcc
equal-weight believ
posit expect cabozantinib
rcc larg price share
limit clinic catalyst ahead
checkmat data earli
believ sale growth
gradual
phase data rcc earli
risk achiev price
cabozantinib earlier stage trial
posit expect new later
stage asset program announc
addit data report support
advanc cabozantinib indic
beyond rcc
slowli expect combin
studi cabozantinib earlier stage
trial succeed
updat antibodi magrolimab drive risk/reward
updat antibodi magrolimab drive risk/reward
pt base dcf use discount rate project free
cash flow base termin valu
onward use termin growth rate project revenu
lead product candid md dlbcl risk-adjust
strong uptak md dlbcl see strong uptak use
broadli across r/r front line dlbcl set base case
gener peak risk-adjust sale also gain
greater share higher-risk share lower-risk md gener peak
risk-adjust sale
modest uptak md dlbcl dlbcl gener risk-
adjust revenu md
gener risk-adjust revenu
assign po probabl success dlbcl md
fail tumor type fail develop stage across
indic result forti seven trade cash value-per-share
overweight forti seven
believ earli clinic data gener
antibodi highli encourag across
oncolog indic could first-in-
class therapi new categori checkpoint
data gener date indic
potenti strong singl agent activ
well activ could complementari
anti-canc agent
progress toward us pivot phiii studi
phib/ii pivot data respons
durabl azacitidin md
phi data studi avelumab
ovarian cancer
phi data studi cetuximab
colorect cancer
risk achiev price
poor efficaci and/or safeti data lead
stronger expect data
losmapimod efficaci phase ii studi drive risk/reward
efficaci phase ii studi drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak
impli us market share fshd adjust use
probabl success po
losmapimod receiv acceler approv phiib data biomark
earli clinic data suffici acceler approv losmapimod
preclin program advanc earli clinic studi
losmapimod approv full phiii program losmapimod meet
primari endpoint phase ii thu demonstr potenti treat fshd
fda requir full clinic program long-term follow-up fshd
patient scenario fulcrum requir conduct phase studi
losmapimod fail losmapimod fail receiv regulatori approv
trade cash value-per-share
believ fulcrum proprietari
target discoveri platform yield
import small molecul target genet
believ losmapimod promis
compound demonstr target
engag fshd higher
typic phiib probabl success clinic
studi see upsid potenti
acceler approv data
believ manag continu
find genet target exploit
small molecul see potenti
target engag muscl expect
studi data demonstr efficaci fshd
patient expect
demonstr efficaci fshd patient
expect
risk achiev price
question valu losmapimod
caus investor regul disregard
avail safeti data gsk prolong
timelin lower probabl
delay timelin posit data
filgotinib ra ibd pipelin asset drive risk/reward
filgotinib ra ibd pipelin asset drive risk/reward
deriv pt discount cash flow analysi use
wacc cash flow forecast expir
filgotinib patent main driver filgotinib
filgotinib still major driver assum greater share ra ipf
oa pipelin asset gener signific sale assum po
adjust peak sale filgotinib ra uc
cd total filgotinib mileston payment
ipf gener peak po adjust global sale
oa gener peak po adjust global sale
filgotinib drive forecast strong contribut ipf oa
pipelin asset assum po adjust peak sale filgotinib
ra uc cd
total filgotinib mileston payment ipf gener
peak po adjust global sale oa gener
peak po adjust global sale
filgotinib pipelin asset fail manag continu invest
 assum cash-per-share valu
equal-weight galapago
believ filgotinib addit pipelin
asset differenti carv
market share competit
filgotinib differenti profil versu
oral competitor xeljanz
olumi believ best class
efficaci cleaner safeti profil
especi anemia across indic
model peak po adjust global sale
filgotinib
filgotinib potenti approv
key inflammatori indic beyond
rheumatoid arthriti includ crohn
spondyl psoriat arthriti
data pipelin asset
ipf oa
encourag enough us incorpor
probabl adjust estim
molecul valuat await
main driver advanc
filgotinib ra ibd along continu
progress ipf oa program
risk achiev price
take signific time phase ii safeti
profil may assur protect
unknown side-effect broader phase
approv risk regulatori approv
assur potenti failur
gain approv one geographi
commerci risk ra market
competit number market
agent along agent develop
filgotinib pipelin product may
darzalex ofatumumab label expans studi coupl matur mid-lat
darzalex ofatumumab label expans studi coupl matur mid-lat
pt deriv dcf use discount
rate termin growth rate revenu driver model
darzalex late-stag partner product ofatumumab
teprotumumab well earli stage proprietari compound
upsid darzalex uptak ofatumumab success ms greater risk-adjust
valu proprietari pipelin assum peak sale darzalex
ofatumumab peak sale pipelin peak sale
continu robust darzalex uptak ofatumumab success ms risk-
adjust valu proprietari pipelin assum peak sale
darzalex ofatumumab peak sale pipelin peak sale
assum blend probabl success
darzalex royalti valu bear case assum darzalex royalti
burden invest pipelin matur assum
greater competit out-year biosimilar cell therapi mm
base case
overweight thesi base
signific upsid skew risk/reward
proprietari pipelin given believ
darzalex royalti plu late-stag
partner pipelin alon account
current valuat genmab
believ darzalex royalti worth
coupl
late-stag pipelin ofatumumab ms
teprotumumab believ
ofatumumab teprotumumab could
believ earli mid-stag
proprietari pipelin under-valued
consensu repres compel
risk/reward valu proprietari pipelin
base case
bull case valuat
ofatumumab label expans ms
asclepio ii
teprotumumab approv
variou proprietari partner product
initi clinic readout
pivot phii data innovatv
tisotumab vedotin cervic cancer earli
risk achiev price
meet consensu expect
ofatumumab could fail late-stag trial
early-stag proprietari asset could fail
durat hcv sale hiv patent expir car-t/pipelin drive risk-reward
durat hcv sale hiv patent expir car-t/pipelin drive risk-reward
less rapid eros hcv franchis strong pipelin realiz drive bull
case hiv product revenu reach hcv busi gener
sale sale yescarta filgotinib
gilead respect
rapid hcv eros lower pipelin success bull case hiv
product revenu reach hcv busi gener sale
sale yescarta filgotinib
gilead respect
stabl hiv revenu quick hcv busi eros minim pipelin
success hiv product revenu hcv busi gener
sale littl pipelin valu
equal-weight gilead believ
offer signific absolut
upsid near-term catalyst
term upsid rel gilead
signific return capit share
repurchas low forward price-to-earnings multipl
offer downsid protect
believ hcv peak us
continu declin modestli
howev believ cash flow gener
robust
hiv gilead done good job
switch nave patient new
stribild complera genvoya
truvada/atripla still hold market
right mean signific number
still need switch howev given time
solid taf switch data believ
least half market switch
car-t gilead acquisit kite provid
potenti renew long term revenu
main driver hiv franchis
hcv franchis car-t franchis
pipelin capit deploy repres
key driver
updat agreement galapago
entitl gilead commerci right
outsid europ jak inhibitor filgotinib
may provid near-term upsid
approv varieti inflammatori
risk achiev price
unexpect competit hiv
rapid hcv eros
appreci consensu
failur car-t achiev signific
market penetr failur meaning
signific delay regulatori
progress jak inhibitor filgotinib
clinic success market penetr voxelotor previous drive
clinic success market penetr voxelotor previous drive
peak penetr voxelotor assum voxelotor demonstr
abil modifi lt marker scd pain sickl crise thrombot event
new standard care assum limit competit gene therapi
peak penetr voxelotor assum clinic success voxelotor
compar success gene therapi voxelotor gene therapi split
voxelotor fail case assum residu cash valu
market signific unmet medic
need voxelotor oral dose potenti
diseas modifi therapi posit well
compet market new therapi
decad market share suggest
us peak sale potenti
earli voxelotor data compel initi
data demonstr reduct sickl
cell improv red blood cell
marker hemoglobin reticulocyt ldh
believ data could translat
clinic outcom includ reduct
sickl crise pain thrombot event
market assumpt leav room
competit current model
peak penetr hbss leav room
gene therapi believ oral dose
could prefer gene therapi could offer
cur therapi could
prefer patient
regulatori progress potenti
commerci launch voxelotor
risk achiev price
regulatori setback failur voxelotor
greater success competitor therapi
gene therapi
epidiolex ramp drive gw share
epidiolex ramp drive gw share
pt deriv dcf use discount rate
termin growth rate beyond valu
program cannabinoid base therapi rare neurolog
epidiolex exce expect drug ramp well label indic
dravet lenox-gastaut strong label use
epidiolex ramp slower expect assum drug ramp well
label indic less steepli anticip off-label use minim
gw market leader medic
applic cannabis-rel intervent
sativex approv eu epidiolex
approv fda
transfer schedul
june food drug
cannabidiol cbd oral solut
treatment seizur two rare sever
form epilepsi lennox-gastaut syndrom
dravet syndrom posit phiii data
could lead tuber sclerosi complex
ad label
believ epidiolex would wide use
treatment refractori epilepsi
on-label off-label
sale ramp epidiolex primari
driver share valu
risk achiev price
gwph stock volatil stock
influenc heavili quarterli
epidiolex sale perform well
payer impos signific restrict
physician hesit prescrib
gwph adr british base
cost expens
sale
interest incom
equival
trade receiv asset
properti equip net
trade payabl
oblig financ leas
trade payabl
oblig financ leas
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
interest incom
depreci properti plant equip
impair properti plant equip
revers impair properti plant equip
amort intang asset
increas provis inventori
decreas defer signatur fee
loss dispos properti plant equip
research develop tax credit receiv
decreas /increas allow doubt debt
chang oper asset liabil
trade receiv asset
trade payabl defer revenu
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas intang asset
proce sale properti plant equip
net use invest activ
flow financ activ
proce exercis share option
proce new equiti issu
expens new equiti issu
proce warrant exercis
underwrit contribut toward expens new equiti issu
repay fit fund
proce financ leas
repay oblig financ leas
effect foreign exchang rate chang cash cash equival
chang equival
equival begin year
equival end year
pt base dcf use discount rate project free
cash flow base termin valu
onward use termin growth rate project revenu
lead product candid tnbc muc
bull case assum achiev greater adopt ww peak risk
adjust sale assum commerci treatment line
mtnbc acceler adopt muc er cancer
base case assum launch mtnbc addit
revenu stream earlier line muc er larg enter
assign risk adjust use mtnbc ww risk adjust sale
bear case assum fail receiv approv indic
stock trade cash valu
equal-weight driven concern
around uncertainti approv timelin
requir follow
sidelin fda
continu believ efficaci
safeti data see signific
unmet need mtnbc believ approv
could see rapid adopt peak
believ obtain multipl
label expans increas asset total
address market studi front line
mtnbc muc breast cancer
remedi approv
phiii data random ascent
studi mtnbc treatment earlier line
data phii muc hormon breast
risk achiev price
management fail correct cmc-relat issu
competit landscap target
therapeut mtnbc muc increas
failur achiev signific label
expans earlier line therapi
jakafi perform oncolog dermatolog pipelin readout drive
jakafi perform oncolog dermatolog pipelin readout drive
deriv price target discount cash flow analysi
factor explicit revenu project use
discount rate termin growth rate
jakafi sale upper rang long-term guidanc clear blockbust
perform key late-stag pipelin asset strong contribut
early-stag pipelin jakafi sale peak total revenu
itacitinib first-lin gvhd gener peak sale ruxolitinib
cream gener peak sale across vitiligo atop
dermat early-stag pipelin contribut aggreg peak sale
jakafi sale midpoint long-term guidanc coupl strong
pipelin realiz jakafi sale manag long-term
guidanc peak total revenu approv
strong uptak late-stag pipelin asset itacitinib first-lin gvhd peak
sale ruxolitinib cream vitiligo atop dermat
aggreg peak sale aggreg peak sale
early-stag pipelin
jakafi sale manag guidanc modest royalti revenu
minim pipelin success jakafi sale peak royalti revenu
jakafi ex-u olumi peak iclusig sale
aggreg peak pipelin revenu
jakafi base busi room
grow hold right jakafi
ruxolitinib ex-u right held
novarti jakafi sale
grown y/i
y/i forecast
continu growth jakafi
meaning contribut label
expans graft versu host diseas
gvhd forecast peak jakafi sale
roughli midpoint
manag long-term guidanc
prior jakafi patent expir
pipelin effort come focu
late throughout
develop broad multi-asset pipelin
believ key area investor focu
phiii asset itacitinib gvhd
ruxolitinib cream vitiligo atop
effort fgfr inhibitor pemigatinib
first phiii readout itacitinib first-lin
gvhd expect first set
phiii ruxolitinib cream data expect
adjust sale itactinib
gvhd ruxolitinib cream
jakafi life cycl extens effort
pemigatinib bladder cancer also
expect
factor grow jakafi sale base
strong contribut late-stag
pipelin result find current
risk/reward valuat balanc
phiii data jakafi itacitinib gvhd
phiii data ruxolitinib cream atop
data pemigatinib bladder cancer
tumor agnost program
addit detail jakafi life cycl
phiii data itacitinib steroid-na acut
gvhd studi
phiii data ruxolitinib cream atop
dermat
risk achiev price
 jakafi sale perform
poor phiii result itacitinib and/or
ruxolitinib cream either due outright safeti
and/or efficaci failur due result
clinic meaning
failur and/or minim success early-
stage pipelin asset
mileston contract revenu
cost expens
product revenu incl definite-liv intang amort
chang fair valu acquisition-rel conting consider
total cost expens
incom loss oper
unreal loss long-term invest
expens relat senior note convers
incom loss provis incom tax
provis incom tax
share use comput net incom loss per share
cash equival
prepaid expens current asset
restrict cash invest
properti equip net
accru current liabil
accumul comprehens incom
total liabil stockhold equiti
flow oper activ
in-process research develop
expens relat senior note convers
unreal loss long-term invest
chang fair valu acquisition-rel conting consider
chang oper asset liabil
prepaid expens asset
accru liabil
net cash provid use oper activ
flow invest activ
acquisit busi net cash acquir
purchas long-term invest
purchas market secur
sale matur market secur
net cash use invest activ
flow financ activ
proce issuanc common stock stock plan
proce issuanc common stock net
paid connect senior note convers
payment conting consider
net cash provid financ activ
effect exchang rate cash cash equival restrict cash invest
net increas cash cash equival restrict cash invest
cash equival restrict cash invest begin period
cash equival restrict cash invest end period
breo anoro success drive risk reward
breo anoro success drive risk reward
pt deriv dcf assum discount rate
breo anoro captur signific share market bull case
assum breo anoro characterist qd dose breo lack
ic anoro drive major share copd asthma
prescript given sluggish launch drug comfort
physician approv laba/icss see scenario unlik
model peak ww sale breo anoro
trelegi
breo anoro sluggish launch case assum breo
anoro gain modest share copd/asthma prescript model peak ww
sale breo anoro trelegi
breo anoro falter commerci bear case assum breo anoro
fail gain commerci traction model ww sale breo anoro
trelegi
underweight see limit
upsid valuat impli
potenti gsk consolid royalti
interest breo/anoro
launch breo anoro
sluggish far
breo qd dose potenti complianc
advantag howev top-line result
breo phiii trial suggest profil similar
patient switch approv laba/icss
compet least initi
laba/ class mean growth anoro
expect maba/tripl combo
cannib sale breo anoro
patient need come laba/
lama/laba take one drug
key driver model includ
royalti breo launch anoro
launch trelegi approv
risk achiev price
breo and/or anoro may sell better
compani may potenti
busi develop transact may
penetr durat ali therapi key valuat driver
penetr durat ali therapi key valuat driver
pt deriv dcf use discount rate
termin growth rate revenu driver model ali
market penetr us japan refractori frontlin
mainten treatment ntm
ali launch japan achiev
penetr respect refractori ntm popul major
patient take form mainten treatment also forecast low
doubl digit penetr frontlin popul us japan peak sale
respect
follow ali launch drug launch japan
reach penetr respect refractori ntm
popul less patient take mainten treatment start
year post launch assum modest frontlin penetr us japan peak
sale respect
ali achiev weak penetr japan
overweight insm given robust
data ali refractori induc ntm
patient derisk approv also provid
modest assumpt chronic dose
opportun note current data argu
investig label
geograph expans japan provid
addit lever see substanti
foreign sale larger ntm popul
prioriti review fda advisori
prepar japan file pmda
follow-up data long-term extens
convert studi full data
risk achiev price
failur reach market restrict
label target small portion
poor long term durabl driven
dropout safeti signal less differenti
standard treatment
delay life cycl manag studi
need obtain robust mainten
tegsedi approv spinraza still focu
tegsedi approv spinraza still focu
pt deriv dcf use discount rate
termin growth rate beyond valu ioni advanc
driven revenu upsid across lead pipelin drug assum spinraza
maintain rapid growth thrombocytopenia concern physician
patient allow tegsedi achiev stronger growth appli modest
pipelin valu drug includ ionis-fxirx ionis-apociii-lrx ionis-
apo -lrx ionis-httrx
spinraza still driver despit tegsedi approv assum spinraza
primari product revenu driver tegsedi sale grow launch limit
appli modest pipelin valu drug includ ionis-fxirx ionis-
apociii-lrx ionis-apo -lrx ionis-httrx
ioni unabl launch addit product base case scenario assum
spinraza sale fall short expect commerci challeng
emerg respect platform pipelin drug
antisens may promis drug
develop platform underweight
ioni believ safeti toler
concern like remain overhang
tegsedi launch underway expect
thrombocytopenia concern weekli
blood monitor like affect sale
see waylivra opportun
limit without clear path us market
spinraza blockbust treatment
type sma develop candid
like increas focu late stage
asset matur pipelin
issu thrombocytopenia particular
spinraza continu grow spinal
muscular atrophi sma increas
emphasi type patient howev
investor remain wari compet gene
share would driven compani
extens develop pipelin
huntington diseas al cvd
risk achiev price
news flow regard either success
failur ioni pipelin could lead
swing share valu
data ioni pipelin alter
efficaci and/or safeti profil
clinic data competit program
alter dynam market ioni
current pursu
licens royalti revenu
cost expens
product revenues/royalti
net incom loss attribut akcea
net incom ioni
non-gaap net incom ioni
cash equival
invest equiti secur regulu therapeut inc
prepaid expens current asset
properti equip net
current portion long-term oblig
defer revenu net current portion
accumul comprehens incom
non-controlling interest akcea
total liabil sharehold equiti
adjust reconcil net loss net cash use oper activ
depreci amort
chang oper asset liabil
pre-paid expens asset
accru expens
net cash provid use oper activ
purchas properti plant equip
purchas market secur
sale matur market secur
net cash use invest activ
proce exercis stock option equiti
proce issuanc common stock
proce issuanc debt
net cash provid financ activ
chang cash cash equival
cash equival begin year
cash equival end year
market secur end year
equal-weight ironwood
expect linzess growth like stabil
multipl quarter
ration post expect spin
cyclerion push ironwood
deeper profit
key revenu driver model
use wacc termin growth rate
linzess becom domin player ib cic market linzess
prefer treatment ib cic domin prescript
product take greater share over-the-counter therapi push past
linzess remain steadi grower linzess gradual grow share ib cic
market beat brand player make headway
expens over-the-counter therapi net sale push past
linzess slow ibs-c cic market slow tough competit take share
risk achiev price
enabl upside/downsid versu
one compani pipelin drug could
achiev superior data lead us
increas expect regard
ration exceeds/fal short
expect lead upside/downsid
million per share basi indic
commerci cost expens
net profit loss sale linzess
ironwood share net profit loss
revenu
revenu
interest expens
interest invest incom
provis incom tax
net incom loss disc oper
million per share basi indic
cash equival
prepaid expens current asset
properti equip net
accru research develop cost
current portion long-term debt
current portion capit leas oblig
long-term liabil discont oper
accumul comprehens incom
total liabil stockhold equiti
million per share basi indic
incom loss discontinu oper
incom loss continu oper
depreci amort
loss gain dispos properti equip
impair loss long-liv asset
remeasur forward purchas contract
write-down inventori net realiz valu
loss facil subleas
accret discount premium invest secur
chang fair valu note hedg warrant
chang fair valu convert note hedg
chang oper asset liabil
chang inventori
prepaid expens current asset
account payabl accru expens
accru research develop cost
net cash use oper activ disc op
net cash use oper activ
purchas available-for-sal secur
sale matur available-for-sal secur
purchas ppe
proce sale properti equip subsidiari
proce sale subsidiari
net cash use invest activ
proce issuanc prefer stock net issuanc cost
proce share issuanc
proce exercis stock option stock purchas plan issuanc common
proce sale noncotrol interest subsidiari
tax benefit stock option
disburs repurchas common stock
proce issuanc note payabl
proce issuanc note hedg warrant
purchas convert note hedg
associ issuanc note payabl
payment borrow capit leas oblig
princip payment debt
net cash provid financ activ
increas cash cash equival
equival begin year
equival end year
data ucd program drive risk/reward
data ucd program drive risk/reward
pt deriv dcf use discount
rate termin growth rate revenu driver model
ucd
greater diagnosi rate larger set address patient ucd
vs base case ucd program gener peak risk-
adjust global sale respect assum
kaleido program approv overt minim patient appli
risk adjust ucd program respect
ucd program approv therapeut receiv signific
patient uptak ucd program gener peak risk-adjust
global sale respect uptak drive
bulk revenu due greater share higher price compar eu
assum kaleido program approv overt
popul appli risk adjust ucd
kaleido pipelin fail ucd program fail kaleido unabl
commerci mmt therapi assum share trade cash
value-per-share case
overweight kaleido thesi
base success commerci
mmt product treatment urea
cycl disord ucd hepat
kaleido take differenti approach
toward leverag gut microbiom
develop synthet analyt
capabl enabl kaleido gener
product candid rapidli kaleido
test mmt candid human non-ind
studi mmt complex carbohydr
molecul relat gra
gener recogn compound
allow kaleido progress directli
late-stag studi ind set-
may facilit speed market
abil progress product candid
strong proof-of-concept human
non-ind studi healthi
toler profil abil reduc
achiev statist signific base
earli yet encourag result
believ could lead posit result
clinic studi patient could progress
becom viabl therapeut ucd
ucd kaleido second lead
program posit top line
data recent report
addit program also plan
infect caus multi-drug resist
mdr pathogen cardiometabol liver
diseas i/o program
current earli believ could
becom futur pipelin driver data
lead ucd program prove
data phii studi ucd
ind
risk achiev price
poor phii data ucd patient
make investor question viabil
platform
neg data microbiom
compani weigh share
regulatori chang compromis
kaleido abil conduct non-ind studi
human could lengthen time
market push product revenu
futur
sale
research develop
gener administr
net loss comprehens loss
oper expens
non- adjust
research develop
gener administr
net incom attribut common stockhold
cash equival
prepaid expens current asset
due relat parti
properti equip net
accru expens current liabil
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
chang fair valu deriv warrant liabil
chang oper asset liabil
prepaid expens current asset
due relat parti
accru expens liabil
net cash use oper activ
purchas properti equip
net cash use invest activ
payment defer issuanc cost
proce issuanc debt net issuanc cost
payment issuanc cost relat debt
proce prefer stock financ net issuanc cost
proce issuanc stock
proce exercis stock option
payment relat capit leas
net cash provid financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
durabl data wet age-rel macular degener drive risk/reward
durabl data wet age-rel macular degener
pt deriv dcf use
discount rate revenu driver model kodiak lead anti-
vegf candid retin diseas
commerci multipl retin diseas strong uptak
commerci wet diabet eye diseas peak
penetr probabl success po total risk-adjust
revenu grow
commerci limit set retin diseas modest
uptak commerci wet peak
penetr probabl success po total risk-adjust revenu
grow peak
fail kodiak unabl develop trade cash
overweight thesi base
success commerci
sever compani commerci
anti-vegf therapi treatment
retin diseas burden monthli
bimonthli treatment reduc long
design extend therapeut
durabl compar current therapi
preclin data well-establish rabbit
model demonstr extend durabl
clean safeti profil
initi clinic data direct phib
phii interim analysi demonstr
demonstr efficaci durabl
wet diabet eye diseas
multipl studi begin
risk achiev price
investor question valu
increas toxic advanc patient
posit data competitor could weigh
market share especi
competitor data arriv prior pivot trial
wait margituximab phiii data posit updat proprietari dart
wait margituximab phiii data posit updat proprietari dart
bispecif platform drive valu
bispecif platform drive valu
advanc therapeut program
better uptak margituximab enoblituzumab bull scenario assum
sale treatment breast gastric cancer scenario also
assum enoblituzumab achiev success trial launch
treatment multipl solid tumor includ pipelin valu potenti
margetuximab peak margetuximab struggl achiev
modest success refractori breast cancer patient revenu
enoblituzumab includ pipelin valu potenti dart platform
failur commerci proprietari partner program macrogen
enoblituzumab gener product relat revenu includ pipelin valu
underweight macrogen though
margetuximab could approv base
inabl differenti os lower
expect respect
target enoblituzumab think could
offer greatest util combin
checkpoint inhibitor would like
see data increas
car-t like efficaci treatment cancer
manufactur packag
dart broadli applic
implement beyond oncolog effort
underway treat autoimmun
infecti diseas dart could effect
safeti toler issu could
present challeng though believ
broad bispecif antibodi platform
substanti potenti data point
mix would like see
improv data gain confid
clinic data dart bispecif
antibodi beyond
posit updat margetuximab head
bla file commerci launch would
bolster downsid support valuat
clinic updat includ
risk achiev price
margetuximab util could greater
expect
posit clinic data pipelin
stock appreci
revenu collabor agreement
revenu govern agreement
cost expens
product revenues/royalti
equival
prepaid expens current asset
properti equip net
defer revenu net current portion
total liabil sharehold equiti
adjust reconcil net loss net cash use oper activ
chang oper asset liabil
pre-paid expens asset
accru expens
net cash provid use oper activ
purchas properti plant equip
purchas market secur
sale matur market secur
payment asset acquisit
net cash use invest activ
proce exercis stock option equiti
proce issuanc common stock
net cash provid financ activ
chang cash cash equival
cash equival begin year
cash equival end year
market secur end year
deriv pt dcf base forecast
mrna base product candid use
discount rate termin growth rate
strong share pipelin program bull case valu
program base case well oncolog relaxin heart
failur fabri program risk adjust vari product
launch begin gener sale
flow flow
success pipelin program base case valu rsv
cmv hmpv pcv kra cancer vaccin program vegf-a
rare diseas program mma pa pku risk adjust vari
product launch begin gener sale
flow
flow
product candid face technology/clinical/regulatori failur
therefor gener revenu share trade cash value-per-share
overweight moderna compani
taken industri approach
develop mrna base therapeut
rapidli gener broad pipelin
program candid enter
mrna drug develop platform
diversifi scalabl compar
competitor mrna space
valid broad partnership
merck astrazeneca
signal gener preclin
earli clinic studi date indic
mrna therapeut activ
across wide varieti modal
indic rang prophylact
cancer vaccin rare diseas believ
mani program repres
abl screen product
candid rapidli due digit
manufactur capabl compani
plan progress five new product
candid clinic everi year
coupl initi proof-of-concept data
area enzym replac
disord would valid key area
approach allow signific
increas pipelin probabl success
addit earli clinic stage data
intratumor i/o local regen
therapeut modal
expect
nomin addit drug candid
risk achiev price
initi data platform
beli investor expect caus
investor write-off subsequ readout
delay abil gener
stronger expect competitor data
mavacamten drive risk/reward
mavacamten drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth rate assum peak us
market share ohcm nhcm dcm
adjust use probabl success po ohcm
po nhcm po dcm
higher po pipelin product assum higher po dcm
ohcm nhcm follow posit data readout
sale estim base conserv market share risk-adjust
base case assumpt describ price target methodolog
precis medicin platform fail unabl advanc product
candid trade cash value-per-share
overweight myokardia
well-defin subgroup unmet medic
need potenti grow beyond
promis phase data
gener lead asset mavacamten
show reduct left ventricular outflow
tract lvot gradient week
provid opportun upsid
enter clinic advanc
mavacamten regulatori updat nhcm
ohcm
risk achiev price
poor efficaci concern safeti data
explorer- hcm lower
probabl success ohcm
concern safeti data
prevent advanc
pt deriv dcf use discount rate
termin growth rate beyond valu nabriva antibiot
lefamulin achiev strong ramp inpati outpati set lefamulin
achiev peak sale contepo reach sale
expect gener might enter market
lefamulin achiev modest share iv use lead oral use discharg set
risk adjust lefamulin sale expect reach
contepo approach risk adjust sale
antibiot unabl get approv stock valu cash
lefamulin novel mechan action
provid need option cabp nabriva
lefamulin first-in-class system
pleuromutilin develop oral iv
use treat community-acquir bacteri
pneumonia cabp lefamulin cabp
target spectrum activ novel
mechan action resist seen
date provid import altern
option treatment cabp
expect gradual commerci adopt
lefamulin sale driven use
inpati set nabriva initi
account said repres
opportun drug
launch rep meant cover
target account gain
formulari access key highli
contepo anoth first-in class antibiot
us contepo first-in-class epoxid
 could potenti approv
cuti although opportun somewhat
key valu driver commerci
ramp lefamulin
risk achiev price
contepo regulatori process could
lefamulin and/or contepo sale fail
potenti addit dilut financ
research premium grant revenu
cost expens
product revenues/royalti
oper expens
cash equival
prepaid expens current asset
properti equip net
accumul comprehens incom loss
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
non-cash incom net
chang oper asset liabil
accru expens liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas term deposit
proce sale available-for-sal secur
transact
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
proce lt debt
effect fx translat
chang equival
equival begin year
equival end year
market secur end year
peak sale neon cancer vaccin program dcf valu
revenu stream repres potenti strateg valu neon
platform compani undergo strateg review process
year-end cash balance/shar neon depriorit develop
compani cancer vaccin program t-cell platform earli
develop us valu near-term catalyst inflect
neon burn cash equival rapidli anticip base case
uw neon therapeut
compani recent depriorit lead cancer
vaccin program previous
compani main area focu
foundat prior thesi
decid focu resourc earlier-
stage neoantigen base t-cell platform
concept t-cell platform
anticip absenc
near-term catalyst outsid potenti
strateg option given compani
current cash runway
expect ntgn share trade cash
value-per-share near-to-mid term
updat compani strateg
trial plan updat lead t-cell
risk achiev price
strateg valu neon platform
materi compani on-going
abil sourc addit financ
near-term materi extend
revenu
research develop
gener administr
income/ loss oper
accret redeem convert prefer stock redempt valu
net incom loss attribut common stock
non- adjust
research develop
gener administr
net incom attribut common stockhold
cash equival
prepaid expens current asset
properti equip net
total liabil stockhold equiti
adjust reconcil net loss net cash use oper activ
depreci amort
net amort premium discount market secur
gains-to-loss sale properti equip
chang oper asset liabil
prepaid expens current asset
accru expens current liabil
net cash use oper activ
purchas market secur
sale matur market secur
purchas properti equip
proce sale properti equip
net cash use invest activ
proce issuanc seri
proce issuanc seri
proce exercis stock option
repurchas unvest restrict common stock
payment initi public offer cost
proce common stock offer
net cash provid financ activ
net decreas increas cash cash
cash equival begin period
cash equival end period
pt deriv dcf use discount
rate assum peak us market share td also model
peak us market share opicapon parkinson translat
ingrezza sale growth beat expect assum peak market share
vy-aadc abl reach market late
unadjust us ingrezza sale td base case assumpt
detail price target methodolog
slower growth td sale bear case assum lower peak us market
share ingrezza td translat peak sale
addit assum vy-aadc unsuccess reach market
overweight thesi driven ingrezza
even though question
whether growth slow think
possibl achiev peak sale
partnership voyag offer
exposur larg market earlier
potenti approv orilissa uterin
potenti approv opicapon
risk achiev price
ingrezza sale growth td may continu
deceler
vy-aadc pivot studi enrol
expect safeti concern aris
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak
impli us market share
nsclc adjust use probabl success po
higher po assum higher po peak share follow posit
base case assumpt describ price target methodolog
immunotherapi platform fail unabl advanc product
candid trade cash value-per-share
overweight nextcur
defin subgroup unmet medic need
potenti expand beyond
sinc express
overlap tumor tumor
respond therapi
phase data provid evid
addit program pipelin
candid find-io platform
provid opportun upsid enter
clinic advanc develop
ind solid tumor
phase proof-of-concept data
phase proof-of-mechan data
phase proof-of-concept data
risk achiev price
poor efficaci and/or safeti data lead
product candid lower po
lack advanc early-stag pipelin
equal-weight base key
unknown risk associ launch
andexxa await addit formulari
updat clariti launch metric
need physician support
factor xa antidot consider bleed
signific potenti devast
complic anticoagul
revenu driver model
launch perform andexxa
us eu row
risk achiev price
andexxa launch could poor
drug may obtain signific uptak
andexxa could face execut
andexxa becom standard care bleed model detail follow
andexxa launch us eu andexxa peak
ww sale
andexxa major driver valuat model detail follow
andexxa launch us eu andexxa peak ww
sale
andexxa achiev base case peak sale assum andexxa
slow ramp modest us penetr andexxa ww sale peak
million except per-shar data
collabor licens revenu
interest incom net
net incom portola non-gaap
million
equival
account interest receiv
prepaid expens current asset
properti equip net
accru liabil
current portion long-term debt
total liabil sharehold equiti
amort premium invest secur
chang reserv uncertain tax posit
issuanc convert prefer stock licens
loss dispos leasehold improv
reevalu prefer stock warrant liabil
chang asset liabil
account interest receiv
pre-paid current long-term asset
accru compens employe benefit
accru liabil
net cash provid use oper activ
purchas properti plant equip
increas restrict
purchas intang asset
purchas short-term invest
proce sale short-term invest
proce matur short-term invest
net cash use invest activ
repay debt
proce issuanc common stock
dividend non-controlling interest srx cardio
proce long-term note payabl net
proce long-term oblig collabor
repurchas unvest common stock
proce issuanc convert prefer stock
proce exercis warrant
net cash provid financ activ
chang due restat
chang equival
equival begin year
equival end year
market secur end year
million
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak us
market share neuronopath gaucher diseas ngd
parkinson diseas mutat pd-gba adjust
use probabl success po respect
higher po pd-gba assum higher po peak share posit
base case assumpt describ price target methodolog
gene therapi platform fail prevail unabl advanc product
candid trade cash value-per-share
overweight prevail compani
patient subpopul unmet medic
preclin data suggest
efficaci safe anim
glucocerebrosidas gcase increas
glycolipid accumul reduc motor
function improv -synuclein
accumul reduc
de-risk vector track
record safeti efficaci support
recent approv novartis/avexi
zolgensma infant sma type
provid opportun
upsid enter clinic
advanc develop
upcom catalyst
begin phase type gaucher
begin phase ftd
begin phase type gaucher
initi phase data type
biomark data
clinic readout
risk achiev price
poor efficaci and/or safeti data lead
product candid lower
lack advanc early-stag pipelin
program osteoporosi oncolog drive risk/reward
program osteoporosi oncolog drive risk/reward
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model tymlo pen abaloparatid patch
osteoporosi well elacestr breast cancer
market leadership growth osteoporosi limit pressur
forteo gener risk-adjust elacestr bull case assum
tymlo pen patch achiev acceler switch forteo user
minim impact gener ww peak sale
pen patch elacestr respect
competit uptak tymlo commerci long term market
transfer patch probabl success po elacestr
base case assum tymlo obtain competit formulari posit
also commerci patch ww sale tymlo
pen patch elacestr respect
loss treatment popul forteo gener poor commerci
patch elacestr fail bear case assum tymlo pen increasingli
pressur entri multipl forteo gener patch fail
substanti grow anabol market ww peak sale
pen patch respect
overweight radiu
encourag trajectori date
osteoporosi drug tymlo lead us believ
tymlo captur sizeabl portion
anabol market
tymlo abaloparatid patch could
differenti product osteoporosi
market current anticip launch
given top line data on-going
phiii studi expect
elacestr gener encourag
data date path forward remain
unclear management aim find partner
asset result assign molecul
likelihood success radiu
continu focu quarterli tymlo
time launch price potenti
enrol updat phiii studi
underway abaloparatid patch
risk achiev price
disappoint launch trajectori tymlo
track prescript data formulari
failur defend market share
gener includ inabl bring
patch market
inabl partner elacestr time
manner lead minim valu contribut
asset near-to-mid term
eylea dupix drive risk-reward
eylea dupix drive risk-reward
better dupix penetr atop dermat asthma assum
us eylea row eylea sarilumab us
sale us dupilumab sale
sarilumab me-too compar actemra strong dupix penetr
asthma atop dermat assum us eylea
row eylea us sarilumab sale
us dupilumab sale
sarilumab still me-too modest dupix launch eylea face
greater branded/biosimilar competit assum us eylea
row eylea us praluent modest row
praluent sale sarilumab us sale
dupilumab sale
equal-weight regeneron
investor heavili scrutin dupix
prescript data sinc launch atop
dermat ad april believ
consensu still factor substanti sale
dupix ad well asthma see
risk/reward skew slightli
posit given steadi launch ad
recent approv asthma emerg
pipelin i/o see littl room near-
dupix initi launch trajectori
dupix encourag ad see
dupix durabl asset asthma
current project dupix
oper profit across atop
dermat asthma
praluent factor watch
develop new trial proceed
sanofi/regeneron
 praluent inflect come quarter
kevzara sarilumab see kevzara
me-too forecast sale
main driver dupix dupilumab
eylea emerg i/o pipelin
risk achiev price
unexpect flatten dupix
dupilumab launch trajectori
disappoint uptak asthma
competit success wamd space
limit uptak i/o asset
success use
success use partner proprietari program drive
technolog partner proprietari program drive
pt deriv dcf use discount rate
termin growth rate beyond valu
proprietari partner gene therapi program
commerci proprietari partner program model
strong uptak indic proprietari program
hofh mp wet respect gener peak
sale partner program mp iiia sma partnership
ultragenyx dimens dmd gene therapi sale gener peak
royalti revenu
commerci proprietari partner program model
modest uptak indic proprietari program
hofh mp wet respect gener peak
sale partner program mp iiia sma partnership
ultragenyx dimens dmd gene therapi revenu gener peak
royalti revenu
failur commerci proprietari partner program
receiv royalti avexi gener product relat
revenu bear case consist cash value-per-share well valu
royalti novartis/avexi sma program eu
overweight
believ compani technolog
platform alreadi broadli licens
across gene therapi landscap provid
potenti transform method
safe effect deliv gene
present known target clear endpoint
reduct hofh reduct
gag accumul mp mp ii
arrang de-risk regenxbio
platform help reduc binari risk
face tradit gene therapi compani
success licens program use
vector deliveri method
reduc technic risk face proprietari
recent posit gene therapi data
help de-risk broader gene therapi
data/upd wet
hofh program
advanc
program mp mp ii respect
updat avexi sma program
technolog license
risk achiev price
pipelin failur partner proprietari
neg safeti efficaci data gene
therapi program develop
either technolog license gene
therapi compani use vector outsid
platform
pt deriv dcf use discount rate
termin growth rate beyond valu rhythm program
orphan genet disord obes
setmelanotid approv launch pomc null lepr defici
setmelanotid data bardet-biedl syndrom bb alstrm
suggest drug could exceed expect indic rais
confid combin phiii trial
setmelanotid like reach market pomc null lepr
defici data bardet-biedl syndrom largest valu driver
incorpor alstrm risk adjust estim peak sale
setmelanotid
setmelanotid fail reach market rhythm trade cash
compel efficaci setmelanotid
two ultra-orphan diseas may result
setmelanotid underway data
expect studi
success would enabl regulatori
bardet-biedl signific
opportun rhythm pursu bardet-biedl
syndrom alstrm syndrom
addit indic rhythm present
data indic suggest
setmelanotid could offer benefit
patient phiii trial examin
indic set begin later year
increas rate diagnosi upon launch
key challeng import lever
setmelanotid commerci success
view increas test diagnosi
rate genet disord obes
patient target ideal candid
setmelanotid therapi current
undiagnos anticip
avail therapeut target
increas test diagnosi rate
believ rhythm would need invest
meaning captur patient
realiz potenti market opportun
key valuat driver perceiv clinic
regulatori risk setmelanotid
syndrom pomc heterozyg obes
risk achiev price
fail clinic trial setmelanotid
rhythm unabl enrol pivot trial
orphan indic
potenti dilut financ
cost expens
product revenues/royalti
net incom loss continu oper
cumul dividend convert prefer share
net loss attribut common stockhold
cash equival
prepaid expens current asset
properti equip net
due relat parti
accru expens current liabil
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
due relat parti
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas short-term invest
matur short-term invest
net use invest activ
flow financ activ
proce issuanc common stock
net proce issuanc seri convert prefer stock
proce lt debt
proce exercis stock option equiti
effect fx translat
chang equival
equival begin year
equival end year
initi rct data diseas ind file drive risk/reward
initi rct data diseas ind file drive risk/reward
pt deriv dcf use discount
rate termin valu onward base
termin growth rate valuat assign credit rubiu rare
diseas oncolog platform
commerci rare diseas oncolog immunolog strong
uptak commerci rare diseas pku gout
homocystinuria oncolog nsclc immunolog pemphigu vulgari
probabl success po pku gout
homocystinuria nsclc pemphigu vulgari total risk-
adjust revenu grow primari
revenu contributor peak pku gout
commerci rare diseas oncolog modest uptak
commerci rare diseas pku gout homocystinuria
nsclc within oncolog pku assign po gout homocystinuria
valu po nsclc assign po pku
commerci product candid launch
total risk-adjust revenu grow
primari revenu contributor peak pku gout
red platform fail rubiu unabl develop rct product candid
trade cash value-per-share
overweight thesi base
broad safe potenti applic
rubiu red platform could gener
diseas oncolog immunolog
pose white blood cell therapi like car-
includ broader applic off-the-
shelf approach improv safeti
rapid scalabl manufactur
preclin data encourag
date particularli rare diseas
platform ind applic lead
product candid
phenylketonuria pku approv fda
key risk across rubiu rare
diseas program deliveri risk
believ posit initi data
patient would address investor concern
significantli derisk rare diseas
program includ refractori gout
initi phi/ii studi
interim data patient
subsequ ind file futur rct
product candid
poor safeti and/or efficaci data rtx-
would like caus investor question
rubiu abil gener effect
investor may subsequ question
valu red platform assign limit
valu rare diseas oncolog
short circul time would
impair commerci prospect
platform could lead limit efficaci
posit data competitor either
platform compani
weigh rubiu share especi
competitor data arriv prior meaning
dataset rubiu
brexanolon launch primari valuat
brexanolon launch primari valuat
brexanolon approv asset
global peak sale potenti
clear unmet need form basi
valuat clear upsid
derisk data mdd
potenti much broader profil
insomnia parkinson diseas addit
indic multi-billon dollar
pipelin broad continu offer
new drug extens effort target
gaba nmda
brexanolon launch steep trajectori provid
bulk valuat strong launch mdd bipolar
insomnia
brexanolon key near-term driver
launch howev form
bulk valuat
brexanolon launch provid bulk valuat
launch mdd bipolar insomnia
approv mdd bipolar insomnia
launch modest
neg safeti efficaci data
therapeut program
unexpect delay clinic
potenti intellectu properti
challeng could impact futur revenu
long-term prospect sarepta dmd franchis drive valu
long-term prospect sarepta dmd franchis
pt deriv dcf use discount rate
termin growth beyond valu sarepta dmd franchis
bull scenario assum exondi achiev rapid launch sale
taper peak penetr achiev also assum aggress sale
exon approv well signific updat gene therapi
base case scenario assum continu strength exondi well
eventu approv golodirsen camisersen risk-adjust
dmd gene therapi total revenu
assum lower peak penetr exondi approv golodirsen
modest sale approv camisersen downstream eros usag
includ revenu altern mutat
overweight thesi base
strong initi dmd genetherapi data
manag abil captur signific
market share dmd gene therapi
product gene therapi remain riski
believ initi data derisk program
provid signific upsid potenti
base busi exon skip drug
pipelin larg divers offer lgmd
potenti upsid driver
time market clinic success
risk achiev price
updat dmd gene therapi
program includ risk relat
manufactur on-going regulatori
failur secur addit regulatori
approv obtain reimburs could
data competitor compani could
either posit neg impact
sarepta posit dmd market
continu uptak adcetri matur mid/late-stag pipelin asset drive risk
continu uptak adcetri matur mid/late-stag pipelin asset drive risk
equal-weight thesi base
estim continu growth adcetri
treatment chl certain subtyp
nhl see key growth driver increas
uptak exist indic potenti
label expans growth earlier line
therapi
enfortumab vedotin current
evalu pivot phii clinic trial
 fda assign pdufa date
vedotin tucatinib potenti
take share metastat cervic
technolog
out-licens number compani
firm entitl mileston royalti
payment collabor base sale
util technolog product
readout adcetri label expans
frontlin hl
upcom fda decis enfortumab
vedotin patient advanc
upcom readout tucatinib
bc neoadjuv bc i-spi
pivot phii readout tisotumab vedotin
cervic cancer
risk achiev price
adcetri revenu estim may
neg impact delay approv
competit product may enter
market erod adcetri market share
enfortumab vedotin tisotumab vedotin
tucatinib initi base limit phi
pt deriv dcf use discount
rate termin growth rate revenu driver model
 adcetri sale eu/row adcetri royalti revenu
estim also includ risk-adjust sale estim partner
product enfortumab vedotin tisotumab vedotin addit
vedotin tucatinib penetr assum continu uptak adcetri
driven label expans model peak canada adcetri sale
peak ex-u royalti seattl genet
assum commerci enfortumab vedotin
peak revenu sourc also model pos-adjust sale
tucatinib profit share sale tisotumab vedotin
continu adcetri growth enfortumab vedotin commerci near
term eventu approv tisotumab vedotin tucatinib assum
continu uptak adcetri driven label expans model peak
canada adcetri sale peak ex-u royalti
seattl genet assum commerci
enfortumab vedotin peak revenu sourc
also model pos-adjust sale tucatinib profit
share sale tisotumab vedotin
slower anticip growth adcetri sale along weak enfortumab
vedotin tucatinib penetr tisotumab vedotin fail achiev
commerci model peak adcetri sale
peak ex-u adcetri sale model peak canada
enfortumab vedotin sale peak tucatinib sale
clinic data defici safeti and/or
efficaci may discov product
candid continu evalu
compani may fail achiev fda
approv label expans pipelin
success develop entinostat hr breast cancer drive risk/reward
success develop entinostat hr breast cancer drive risk/reward
assum entinostat achiev rapid uptak hr bc assum combin
hormon therapi hr breast cancer exce base case expect
assum modest uptak hr bc assum modest hr her- breast cancer
sale project risk adjust
assum entinostat fail achiev suffici clinic result hr
equal-weight syndax
develop class hdac entinostat
near-term compani stock
leverag outcom phiii
trial hr breast cancer although
menin-llr program intrigu
confid entinostat/checkpoint
inhibitor combin wane somewhat
howev could eventu path
forward inflam tumor nsclc
melanoma
stock valuat highli link
success phiii trial
risk achiev price
neg safeti efficaci data
therapeut program
unexpect challeng checkpoint
inhibitor i/o therapi gener
could dampen syndax opportun
potenti intellectu properti
challeng could impact futur revenu
cost expens
product revenues/royalti
incom loss attribut stockhold
net incom loss attribut common stockhold
equival
market secur cash
prepaid expens current asset
properti equip net
defer revenu net current portion
total liabil sharehold equiti
adjust reconcil net loss net cash use oper activ
chang oper asset liabil
pre-paid expens asset
accru expens
net cash provid use oper activ
purchas properti plant equip
purchas market secur
sale matur market secur
payment asset acquisit
net cash use invest activ
proce exercis stock option equiti
proce issuanc common stock
net cash provid financ activ
chang cash cash equival
cash equival begin year
restrict includ line item
cash equival end year
market secur end year
crysvita drive risk/reward
crysvita
pt deriv dcf use discount
rate model peak risk-adjust revenu addit
peak ww sale mepsevii crysvita
model peak unadjust ww sale
adjust
use probabl success po
posit data readout better-than-expect launch assum higher
po po follow subsequ
confirm posit data cohort cohort respect
support advanc program phase addit assum
better-than-expect launch lead greater peak market share
crysvita mepsevii
strong crysvita launch base case assumpt describ price
target methodolog
pipelin product fail bear case assum fail
approv call question mepsevii crysvita face
slower adopt us
overweight rate base
belief street undervalu
crysvita launch remain strong
potenti upsid greater adopt
adult famili
data promis
confid program
like ultragenyx third
compani continu deepen
diversifi pipelin new gene therapi
mrna candid
updat phase cohort
data phase cohort
patient
potenti approv lc-faod
risk achiev price
crysvita mepsevii may face
commercial/reimburs challeng
achiev suffici patient adopt
data subsequ indic
pipelin candid may succeed
even data posit fda may
probabl success anti-ag market well osteoarthr knee
probabl success anti-ag market well osteoarthr knee
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model osteoarthr oa addit
success oa drive peak ww sale probabl
success coupl probabl success penetr anti-ag
market broadli
success oa drive peak ww sale probabl
success coupl probabl success penetr anti-ag
market broadli
program fail valu compani cash
manag pioneer novel
biolog senesc cell
opportun deliv step-funct chang
treatment chronic diseas
preclin model support
impact sasp factor senesc
suggest benefit
remov senesc cell
oa offer proof-of-concept model
clear biomark clinic endpoint
follow-up long-term chronic data
addit ind file follow-up
product includ eye
risk achiev price
biolog approach
novel initi program fail falter
investor like heavili discount
competit space
privat
initi oa program may right
target test senesc cell snc
follow-up period dose period
medicin may long enough
kinet remov snc see
therapeut respons known
progress actr boxr platform drive risk/reward
progress actr boxr platform drive risk/reward
base case valuat deriv explicit forecast actr
boxr product discount termin growth rate
efficaci solid tumor modest success liquid tumor
progress nhl highli differenti data construct gener
peak risk-adjust sale solid tumor platform gener
peak sale across actr boxr platform
efficaci solid tumor minim contribut liquid tumor
progress nhl gener peak risk-adjust sale
solid tumor platform gener peak sale across actr
actr boxr product candid fail across solid liquid tumor actr
boxr product candid fail aggress cash burn continu
result share eventu trade low cash value-per-share
overweight unum base
view technolog could provid
robust therapeut window compar
especi solid tumor
believ recent realloc
resourc solid tumor platform
sensibl find progress boxr
believ umrx current valuat
level combin potenti cell
therapi solid tumor present attract
risk/reward profil head key solid
tumor catalyst
enrol safeti updat
trastuzumab solid tumor
initi efficaci data
studi
ind file late
updat dose escal data attck-
nhl decis
develop path forward
risk achiev price
concern safeti signal
safeti updat expect
ind file delay beyond
abil financ broader
develop boxr platform solid
cost expens
product revenues/royalti
loss discontinu oper net tax
loss sale discontinu oper net tax
net loss comprehens loss
equival
prepaid expens current asset
properti equip net
defer revenu net current portion
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
pre-paid expens asset
accru expens liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas market secur
sale matur market secur
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
chang equival
equival begin year
equival end year
market secur end year
triplet approv
triplet approv uptak life-cycl manag oper margin drive
uptak life-cycl manag oper margin drive
ww penetr across cf medicin life-cycl extens extend
franchis bull case assum higher penetr tripl
therapi het/min homozygot patient initi tripl data
replic phiii therapi launch ww sale
cf aatd us eu commerci success key
risk-adjust tripl combo success mainten key cf franchis
life-cycl extens base case assum penetr tripl
combin homozygot heterozygot risk-adjust peak ww
sale cf aatd
modest orkambi uptak tripl combin fail achiev approv
het/min popul bear case assum row us
penetr orkambi homozyg cf patient total peak ww sale
cf aatd therapi peak
overweight vertex believ
initi tripl data replic phiii
studi see vertex clear leader
cf therapi believ manag
potenti deliv ep
initi phi phii data tripl
het/min popul better
kalydeco-lin efficaci
homozyg popul thu includ
risk-adjust tripl combin revenu
base case
efficaci data aatd mice model
suggest efficaci corrector human
therefor model includ risk-
adjust revenu corrector
believ potenti
competit believ vertex
signific advantag posit
on-market doubl combin in-
share competitor long-
main driver vertex phiii
tripl studi time approv launch
uptak current therapi
orkambi/kalydeco uptak in-
develop therapi tez/iva triplet
risk achiev price
combo penetr fall short
kalydeco sale fail meet
data clinic candid tripl
combin fail meet expect
data competit exce
clinic trial nda file
inebilizumab nmosd drive risk/reward
inebilizumab nmosd drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak us
market share nmosd adjust use probabl
inebilizumab approv nmosd faster uptak assum
po higher peak share quicker ramp launch also assum higher
po pipelin program mg sjgren kidney
base case assumpt describ price target methodolog
fda request addit data result delay approv assum
lower po inebilizumab nmo assum slower uptak
overweight viela compani
develop treatment autoimmun
inebilizumab clinic de-risk
nmosd follow posit phase data
think like approv mid-
believ inebilizumab like one
favor treatment front-lin
addit
indic inebilizumab provid
opportun upsid
upcom catalyst
begin phase studi inebilizumab
begin phase studi kidney
potenti approv inebilizumab
risk achiev price
fda may approv inebilizumab
launch inebilizumab nmosd may
slower expect due intens
competit soliri satralizumab
lack advanc pipelin
vy-aadc parkinson drive risk/reward
vy-aadc parkinson drive risk/reward
pt deriv dcf use discount
rate model unadjust ww vy-aadc revenu
voyag receiv profit share us low- high-
teen royalti eu sale risk-adjust use po vy-
huntington model peak unadjust ww sale
adjust use po
optimist view vy-aadc scenario assum po
follow strong long-term data greater market share vy-aadc us
eu
vy-aadc us launch base case assumpt describ
price target methodolog
gene therapi platform fail bear case assum voyag unabl
advanc product candid trade cash value-per-share
equal-weight rate base limit
clinic catalyst
major valuat driven
vy-aadc parkinson
file ind huntington
vy-aadc phase data
vy-aadc phase data
risk achiev price
enrol faster expect addit vy-
aadc data increas investor confid
program expect
earli stage candid advanc
clinic vy-aadc pivot studi
enrol expect safeti concern aris
longer term data reflect strong
durabl respons
pt deriv dcf use discount rate
glepaglutid dasiglucagon demonstr superior profil product
differenti sb hypoglycemia respect lead acceler
uptak versu current standard care
dasiglucagon glepaglutid competit pipelin asset
approv view competit standard care
late state pipelin falter dasiglucagon glepaglutid fail reach
dasiglucagon glepaglutid driver
dasiglucagon glepaglutid driver
strong pipelin support ow rate
view zealand strong pipelin
led two therapi glepaglutid
dasiglucagon improv version
standard care drug
dasiglucagon could better offer
dasiglucagon rescu medic
sever hypoglycemia repres
conveni offer current market
glucagon like drive strong uptak
therapi approv potenti futur use
artifici pancrea system orphan
repres upsid estim
glepaglutid next-gen
could improv profil teduglutid
earlier featur short half
life requir complex multi-step
reconstitut process prior administr
glepaglutid enhanc stabil
extend half life allow drug
glepaglutid dasiglucagon success
risk achiev price
fail clinic trial pipelin candid
dasiglucagon glepaglutid
potenti need rais dilut equiti
dkk million
cost expens
product revenues/royalti
nsdq zeal dkk million
prepaid expens current asset
properti equip net
total liabil sharehold equiti
nsdq zeal dkk million
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
chang work capit
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas secur
purchas invest
transfer to/from restrict cash relat royalti bond
transfer restrict cash royalti bond interest payment
net use invest activ
flow financ activ
proce issuanc share relat exercis warrant
proce issuanc common stock
repay royalti bond
effect exchang rate
chang equival
equival begin year
equival end year
market secur end year
